<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006579</article-id><article-id pub-id-type="pmc">PMC11859798</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020212</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00212</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetics of Snake Antivenom Following Intravenous and Intramuscular Administration in Envenomed Large Animal Model</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gamulin</surname><given-names>Erika</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-pharmaceutics-17-00212" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Mateljak Luka&#x0010d;evi&#x00107;</surname><given-names>Sanja</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceutics-17-00212" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2786-0054</contrib-id><name><surname>Lang Balija</surname><given-names>Maja</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceutics-17-00212" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Smajlovi&#x00107;</surname><given-names>Ana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af2-pharmaceutics-17-00212" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Vnuk</surname><given-names>Dra&#x0017e;en</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af2-pharmaceutics-17-00212" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Gulan Harcet</surname><given-names>Jadranka</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af3-pharmaceutics-17-00212" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Tomi&#x0010d;i&#x00107;</surname><given-names>Maja</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af3-pharmaceutics-17-00212" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>He&#x00107;imovi&#x00107;</surname><given-names>Ana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af3-pharmaceutics-17-00212" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7370-0997</contrib-id><name><surname>Halassy</surname><given-names>Beata</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-pharmaceutics-17-00212" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Kurtovi&#x00107;</surname><given-names>Tihana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-pharmaceutics-17-00212" ref-type="aff">1</xref><xref rid="c1-pharmaceutics-17-00212" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Karbownik</surname><given-names>Agnieszka</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Kara&#x0017a;niewicz-&#x00141;ada</surname><given-names>Marta</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Szkutnik-Fiedler</surname><given-names>Danuta</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00212"><label>1</label>Centre for Research and Knowledge Transfer in Biotechnology, University of Zagreb, Rockefellerova 10, HR-10000 Zagreb, Croatia; <email>egamulin@unizg.hr</email> (E.G.); <email>smatelja@unizg.hr</email> (S.M.L.); <email>mlbalija@unizg.hr</email> (M.L.B.); <email>bhalassy@unizg.hr</email> (B.H.)</aff><aff id="af2-pharmaceutics-17-00212"><label>2</label>Clinic for Surgery, Orthopaedics and Ophthalmology, Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, HR-10000 Zagreb, Croatia; <email>asmajlovic@vef.unizg.hr</email> (A.S.); <email>dvnuk@vef.unizg.hr</email> (D.V.)</aff><aff id="af3-pharmaceutics-17-00212"><label>3</label>Croatian Institute of Transfusion Medicine, Petrova 3, HR-10000 Zagreb, Croatia; <email>jadranka.gulan-harcet@hztm.hr</email> (J.G.H.); <email>maja.tomicic@hztm.hr</email> (M.T.); <email>ana.hecimovic@hztm.hr</email> (A.H.)</aff><author-notes><corresp id="c1-pharmaceutics-17-00212"><label>*</label>Correspondence: <email>tihana.kurtovic@unizg.hr</email></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>212</elocation-id><history><date date-type="received"><day>08</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>27</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>04</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background</bold>: The parenteral administration of antivenoms is the mainstay in snakebite envenoming therapy. The standardized protocol does not exist, but it is agreed that the intravenous (<italic toggle="yes">i.v.</italic>) route is more effective than the others, especially the intramuscular (<italic toggle="yes">i.m.</italic>) route, based on the monitoring of venom/antivenom pharmacokinetics in the systemic circulation. Recent evidence suggests that the lymphatic system may be crucial in abolishing venom action. <bold>Methods:</bold> A preclinical study was performed to determine the optimal administration route with emphasis on venom/antivenom interplay in both the blood and lymph of experimentally envenomed sheep. Timed level measurements were used to compare the antivenom effect on the decrement of venom quantities in both relevant body compartments. Hematological and coagulation parameters, as well as proportions of developed anti-antivenom IgGs, were evaluated. <bold>Results:</bold> The <italic toggle="yes">i.m.</italic> antivenom resulted in faster and greater lymphatic absorption and complete neutralization of the venom, whereas the <italic toggle="yes">i.v.</italic> antivenom only slowed its absorption. The total amount of venom reaching the lymph (AUC<sub>0-<italic toggle="yes">t</italic></sub>) was two times lower after <italic toggle="yes">i.m.</italic> administration. In the systemic circulation, <italic toggle="yes">i.m.</italic> antivenom had a lower peak concentration (<italic toggle="yes">c</italic><sub>max</sub>) and a longer time to reach it (<italic toggle="yes">t</italic><sub>max</sub>). However, the total venom exposure was three times lower than with <italic toggle="yes">i.v.</italic> antivenom. Irrespective of the treatment approach, both groups showed improvement in blood disorders with no significant difference in humoral response against equine F(ab&#x02019;)<sub>2</sub> fragments. <bold>Conclusions:</bold>&#x000a0;<italic toggle="yes">I.m.</italic> administration proved to be a viable option for the snakebite management.</p></abstract><kwd-group><kwd>Zagreb antivenom</kwd><kwd><italic toggle="yes">Vipera ammodytes</italic> venom</kwd><kwd>administration route</kwd><kwd>pharmacokinetics</kwd><kwd>lymphatic system</kwd><kwd>systemic circulation</kwd><kwd>immunotherapy</kwd><kwd>drug efficacy</kwd></kwd-group><funding-group><award-group><funding-source>Croatian Science Foundation</funding-source><award-id>UIP-2020-02-1317</award-id></award-group><award-group><funding-source>Young researchers&#x02019; career development project&#x02014;training of new doctoral students</funding-source><award-id>DOK-2021-02-1416</award-id></award-group><funding-statement>This work was supported by the Croatian Science Foundation, grant number UIP-2020-02-1317 to T.K. and &#x0201c;Young researchers&#x02019; career development project&#x02014;training of new doctoral students&#x0201d;, grant number DOK-2021-02-1416 to T.K.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00212"><title>1. Introduction</title><p>Snakebite envenoming is a major public health burden [<xref rid="B1-pharmaceutics-17-00212" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-17-00212" ref-type="bibr">2</xref>]. Approximately 2.7 million people suffer from its consequences each year, and more than 400,000 of those who survive remain permanently disabled. The World Health Organization (WHO) has developed a comprehensive strategy to reduce the devastating effects of envenoming by ensuring global access to safe and effective antivenoms as the only specific and validated life-saving therapeutics. Antivenoms are produced from animal-derived hyperimmune plasma and consist of whole IgGs or their derivative products (Fab or F(ab&#x02019;)<sub>2</sub> fragments), which are capable of neutralizing and reversing lethal and tissue-damaging toxic effects in envenomed individuals [<xref rid="B3-pharmaceutics-17-00212" ref-type="bibr">3</xref>]. Their parenteral administration still remains the mainstay of envenoming therapy [<xref rid="B4-pharmaceutics-17-00212" ref-type="bibr">4</xref>], a principle that dates back to the 19th century [<xref rid="B5-pharmaceutics-17-00212" ref-type="bibr">5</xref>]. Today, the entire world faces a critical and long-standing shortage of antivenoms, primarily affecting low-income [<xref rid="B6-pharmaceutics-17-00212" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-17-00212" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-17-00212" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-17-00212" ref-type="bibr">9</xref>], but also high-income, countries [<xref rid="B10-pharmaceutics-17-00212" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-17-00212" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceutics-17-00212" ref-type="bibr">12</xref>], whose alleviation requires the development of feasible and profitable production strategies, rational use and the implementation of well-designed treatment protocols [<xref rid="B6-pharmaceutics-17-00212" ref-type="bibr">6</xref>,<xref rid="B13-pharmaceutics-17-00212" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-17-00212" ref-type="bibr">14</xref>].</p><p>The efficacy of antivenom-based immunotherapy depends on the ability of venom-specific antibodies to find themselves in the same distribution space as the venom components, redistribute and ultimately eliminate them, thereby avoiding any adverse effects [<xref rid="B15-pharmaceutics-17-00212" ref-type="bibr">15</xref>]. Beyond the preclinical neutralization potential [<xref rid="B16-pharmaceutics-17-00212" ref-type="bibr">16</xref>], the efficacy of antivenoms is influenced by several factors. The route of administration is emerging as one of the most important [<xref rid="B17-pharmaceutics-17-00212" ref-type="bibr">17</xref>]. There is no standardized protocol for antivenom administration across Europe, similarly as in many other regions of the world [<xref rid="B18-pharmaceutics-17-00212" ref-type="bibr">18</xref>]. It is a WHO recommendation that, whenever possible, snake antivenoms should preferably be given intravenously (<italic toggle="yes">i.v.</italic>) [<xref rid="B19-pharmaceutics-17-00212" ref-type="bibr">19</xref>] as a principle of harmonization of their pharmacokinetics with that of the target venom, since this should eliminate the restraint associated with the intramuscular (<italic toggle="yes">i.m.</italic>) route [<xref rid="B13-pharmaceutics-17-00212" ref-type="bibr">13</xref>,<xref rid="B20-pharmaceutics-17-00212" ref-type="bibr">20</xref>]. Until recently, almost all studies of venom and antivenom pharmacokinetics have been directed solely toward time measurements in the systemic circulation [<xref rid="B21-pharmaceutics-17-00212" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceutics-17-00212" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceutics-17-00212" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceutics-17-00212" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-17-00212" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-17-00212" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-17-00212" ref-type="bibr">27</xref>]. It appeared that antivenoms administered <italic toggle="yes">i.m.</italic> reach the bloodstream slowly and inefficiently, with a significantly longer time required to reach the maximum concentration, followed by poor bioavailability [<xref rid="B21-pharmaceutics-17-00212" ref-type="bibr">21</xref>,<xref rid="B23-pharmaceutics-17-00212" ref-type="bibr">23</xref>,<xref rid="B28-pharmaceutics-17-00212" ref-type="bibr">28</xref>]. Such pharmacokinetic behavior is not adequately adapted, both in terms of timing and quantity, to the much faster arrival of subcutaneous (<italic toggle="yes">s.c.</italic>) or <italic toggle="yes">i.m.</italic> venom to the bloodstream [<xref rid="B29-pharmaceutics-17-00212" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-00212" ref-type="bibr">30</xref>]. On the contrary, with <italic toggle="yes">i.v.</italic> application, the entire antivenom fraction is immediately available in the systemic circulation, allowing for the prompt neutralization of rapidly absorbed venom components [<xref rid="B31-pharmaceutics-17-00212" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-17-00212" ref-type="bibr">32</xref>]. As a result, the widespread belief that <italic toggle="yes">i.v.</italic> application is more effective than <italic toggle="yes">i.m.</italic> has been established. Accordingly, it has been given priority by authorities despite the lack of randomized controlled trials. The WHO advises the <italic toggle="yes">i.m.</italic> route only as a substitute strategy at peripheral first-aid stations far from medical care and in the cases where <italic toggle="yes">i.v.</italic> access has proved impossible, as it can cause extreme pain and an increased risk of intracompartmental pressure [<xref rid="B19-pharmaceutics-17-00212" ref-type="bibr">19</xref>]. Nevertheless, the <italic toggle="yes">i.m.</italic> route is still widely used as a first-aid measure in snakebite management, with a number of manufacturers prescribing their products for <italic toggle="yes">i.m.</italic> and/or <italic toggle="yes">s.c.</italic> application [<xref rid="B33-pharmaceutics-17-00212" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceutics-17-00212" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-17-00212" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-17-00212" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-17-00212" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-17-00212" ref-type="bibr">38</xref>] and publications confirming its positive influence on the clinical outcome [<xref rid="B39-pharmaceutics-17-00212" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-17-00212" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceutics-17-00212" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-17-00212" ref-type="bibr">42</xref>].</p><p>However, <italic toggle="yes">i.m.</italic> administration may not be such an incomprehensible concept if one considers that snake venoms are complex mixtures of proteins of variable molecular weight [<xref rid="B43-pharmaceutics-17-00212" ref-type="bibr">43</xref>], which, in most envenomation cases, are injected into the interstitial space either by the <italic toggle="yes">i.m.</italic> or the <italic toggle="yes">s.c.</italic> route, and whose absorption into the bloodstream may occur via blood or lymph capillaries, depending on their size [<xref rid="B44-pharmaceutics-17-00212" ref-type="bibr">44</xref>]. It is generally accepted that those of viperids are primarily absorbed through the lymphatic system, which serves as a depot for their continuous release into the systemic circulation [<xref rid="B45-pharmaceutics-17-00212" ref-type="bibr">45</xref>]. This lymphatic absorption acts as a &#x0201d;gateway&#x0201c; for the entry and distribution of venom components, influencing their systemic availability and ability to reach target organs [<xref rid="B46-pharmaceutics-17-00212" ref-type="bibr">46</xref>]. Low-molecular-weight elapid toxins are known for their ability to bypass the lymphatic system [<xref rid="B28-pharmaceutics-17-00212" ref-type="bibr">28</xref>,<xref rid="B47-pharmaceutics-17-00212" ref-type="bibr">47</xref>]. They can be delivered directly from the injection site into the bloodstream and reach their sites of action in a very short time. Unlike venoms, antivenoms have a uniform composition containing only large molecules. Therefore, when administered <italic toggle="yes">i.m.</italic>, they can reach the central compartment only by slow diffusion into the initial lymphatics. Here, immediate contact with the venom coming from the injection site to the lymph and timely prevention of its escape into the bloodstream can be achieved.</p><p>In fact, as demonstrated recently, <italic toggle="yes">i.v.</italic> antivenom-mediated neutralization occurs not only in the systemic circulation but also in the lymphatic system [<xref rid="B48-pharmaceutics-17-00212" ref-type="bibr">48</xref>]. In particular, there is evidence that the lymphatic system not only plays a role in venom distribution and bioavailability but also serves as a compartment where antivenom, extravasated from the blood after <italic toggle="yes">i.v.</italic> administration, eliminates a large share of venom before the lymph reaches the systemic circulation [<xref rid="B48-pharmaceutics-17-00212" ref-type="bibr">48</xref>]. Considering that the antivenom may have substantial neutralizing activity in the lymphatic system, the matching of venom/antivenom pharmacokinetics in the systemic circulation may not be the best, or at least only, indicator of therapeutic success. The role of <italic toggle="yes">i.m.</italic> antivenom in the elimination of lymph-absorbed venom may be even greater, but it has not been studied, highlighting an important gap in existing knowledge. More importantly, considering the relevance of both body compartments, blood and lymph, <italic toggle="yes">i.v.</italic> and <italic toggle="yes">i.m.</italic> administration routes have not been compared in a consolidated manner.</p><p>The main objective was to compare two common routes of antivenom administration in a comprehensive preclinical study involving F(ab&#x02019;)<sub>2</sub> antivenom specific for the venom of <italic toggle="yes">Vipera ammodytes</italic>, a species of high medical importance in Southeastern Europe [<xref rid="B49-pharmaceutics-17-00212" ref-type="bibr">49</xref>], which causes severe envenomation, local edema and coagulation disorders [<xref rid="B32-pharmaceutics-17-00212" ref-type="bibr">32</xref>] and determines which treatment approach is more effective in overcoming either the whole venom or its neurotoxic fraction, consisting of ammodytoxins (Atxs) in both relevant body compartments where neutralization occurs. To address the issue, sheep were employed as an experimental model suitable for studying the lymphatic absorption of <italic toggle="yes">s.c.</italic> injected proteins with results comparable to those in humans [<xref rid="B46-pharmaceutics-17-00212" ref-type="bibr">46</xref>,<xref rid="B50-pharmaceutics-17-00212" ref-type="bibr">50</xref>]. Their size facilitates the performance of surgical techniques and the collection of biological samples in the required quantities without compromising their health [<xref rid="B51-pharmaceutics-17-00212" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceutics-17-00212" ref-type="bibr">52</xref>]. The second objective was to provide information on the effectiveness of <italic toggle="yes">i.m.</italic> and <italic toggle="yes">i.v.</italic> antivenoms in terms of their ability to reverse disturbances affecting the main hematological and coagulation parameters after experimentally induced envenoming. The final objective was to give an insight into the safety profiles of <italic toggle="yes">i.m.</italic> and <italic toggle="yes">i.v.</italic> antivenoms, as assessed by the evaluation of antibodies raised against equine F(ab&#x02019;)<sub>2</sub> fragments.</p><p>In summary, this study will either provide additional evidence for the <italic toggle="yes">i.v.</italic> route precedence or disprove the negative connotation associated with the <italic toggle="yes">i.m.</italic> administration, proving it to be an equally good or even better concept from the standpoint of preclinical assessment. Additionally, the platform here described may provide a valuable tool for the design of new or improved treatment protocols, not only for snakebite management but also for other medical conditions targeted by immunotherapeutics, particularly those based on monoclonal antibodies, whose breakthrough into clinical practice is now more evident than ever, offering the opportunity to create more effective and safer strategies for the enhancement of patient outcomes.</p></sec><sec id="sec2-pharmaceutics-17-00212"><title>2. Materials and Methods</title><sec id="sec2dot1-pharmaceutics-17-00212"><title>2.1. Chemical, Reagents, Snake Venom and Antivenom</title><p>The rabbit anti-horse IgG conjugated with horseradish peroxidase (HRP-anti-horse IgG) (product number: A6917-1ML; batch number: 0000161499) and the rabbit anti-guinea pig IgG conjugated with horseradish peroxidase (HRP-anti-guinea pig IgG) (product number: A5545-BULK; batch number: 0000119340) were obtained from Sigma-Aldrich (St. Louis, MO, USA). The horseradish peroxidase-conjugated goat anti-equine F(ab&#x02019;)<sub>2</sub> antibody (HRP-anti-equine F(ab&#x02019;)<sub>2</sub> IgG) (product number: ABIN101430; batch number: 45751) and rabbit anti-sheep IgG (HRP-anti-ovine IgG) (product number: ABIN102255; batch number: 34337) were from Antibodies Online (Aachen, Germany). <italic toggle="yes">O</italic>-phenylenediamine dihydrochloride (OPD), Tween 20 and bovine serum albumin (BSA) were from Sigma-Aldrich (St. Louis, MO, USA). Chemicals for buffers and solutions were from AppliChem (Darmstadt, Germany) unless stated otherwise. <italic toggle="yes">V. ammodytes ammodytes</italic> (<italic toggle="yes">Vaa</italic>) venom was collected by milking snakes kept at the Institute of Immunology Inc., Zagreb, Croatia. It was desiccated at room temperature and stored in the dark at 4 &#x000b0;C. Before this study, <italic toggle="yes">Vaa</italic> venom solution was prepared in 0.9% NaCl at a concentration of 10 mg mL<sup>&#x02212;1</sup>, and its lethal dose was determined. &#x0201c;Zagreb&#x0201d; antivenom (batch number 190/2) was provided by the Institute of Immunology Inc., Zagreb, Croatia, and stored at 4 &#x000b0;C. Recombinant ammodytoxin A (AtxA) was provided by the Institute Jo&#x0017e;ef Stefan, Ljubljana, Slovenia.</p></sec><sec id="sec2dot2-pharmaceutics-17-00212"><title>2.2. Animals</title><p>This study was conducted on a total of 16 mixed female Pramenka sheep (weighing about 50 kg) obtained from a local family farm. The animals used for blood sampling were in the experiment for two weeks. Those used for lymph sampling were in the experiment for six hours and were closely monitored using a clinical assessment form, with more frequent checks on behavior and body weight. They were housed in enriched enclosures with sufficient floor space to allow them to lie down, chew their cud, and move freely. The entire enclosure had a solid floor covered with straw, a ventilation system with a temperature of 18&#x02013;21 &#x000b0;C, a relative humidity of 30&#x02013;50%, with a minimum of 6 h of darkness, and unrestricted access to water and food consumed ad libitum.</p></sec><sec id="sec2dot3-pharmaceutics-17-00212"><title>2.3. Ethical Statement</title><p>All animal experiments complied with the ARRIVE guidelines 2.0 [<xref rid="B53-pharmaceutics-17-00212" ref-type="bibr">53</xref>] and were carried out in accordance with EU Directive 2010/63/EU on the protection of animals used for scientific purposes. Animal experimentation was approved by the Croatian Ministry of Agriculture, Veterinary and Food Safety Directorate (UP/I-322-01/20-01/62, permission no. 525-10/1338-21-5). The approval was based on the positive opinion of the National Ethical Committee (EP 315/2021).</p></sec><sec id="sec2dot4-pharmaceutics-17-00212"><title>2.4. Study Design</title><p>Sixteen sheep were given a 20 mg dose of venom, applied <italic toggle="yes">s.c.</italic> They were divided into two groups, according to the route of antivenom administration (<xref rid="pharmaceutics-17-00212-f001" ref-type="fig">Figure 1</xref>). Group 1 (<italic toggle="yes">n</italic> = 8) received an <italic toggle="yes">i.m.</italic> antivenom injection (4 mL of a 100 mg mL<sup>&#x02212;1</sup> solution). Group 2 (<italic toggle="yes">n</italic> = 8) obtained <italic toggle="yes">i.v.</italic> antivenom as an infusion (4 mL of a 100 mg mL<sup>&#x02212;1</sup> solution diluted in 100 mL of 0.9% NaCl) over 30 min. In group 1, half of the animals were used for lymph sampling (L<italic toggle="yes"><sub>i.m.</sub></italic>) and the other half for blood sampling (S<italic toggle="yes"><sub>i.m.</sub></italic>). Similarly, in group 2, half of the animals were used for lymph sampling (L<italic toggle="yes"><sub>i.v.</sub></italic>) and the other half for blood sampling (S<italic toggle="yes"><sub>i.v.</sub></italic>).</p></sec><sec id="sec2dot5-pharmaceutics-17-00212"><title>2.5. Surgical Procedure for Lymph Sampling</title><p>Sheep were premedicated with xylazine (0.1 mg/kg <italic toggle="yes">i.m.</italic>) and ketamine (7.5 mg/kg <italic toggle="yes">i.m.</italic>). After placement of the <italic toggle="yes">i.v.</italic> catheter, fentanyl (2 &#x003bc;g/kg <italic toggle="yes">i.v.</italic>) and diazepam (0.25 mg/kg <italic toggle="yes">i.v.</italic>) were administered, and anesthesia was induced with thiopental (3.1 mg/kg <italic toggle="yes">i.v.</italic>). Sheep were then intubated with an endotracheal tube (10 mm internal diameter) during the surgical phase of anesthesia. Intraoperative anesthesia was maintained with the inhalational anesthetic isoflurane (1.5&#x02013;2%), and continuous infusion of the opioid analgesic fentanyl (0.1&#x02013;0.2 &#x000b5;g/kg/min <italic toggle="yes">i.v.</italic>) provided additional analgesia. Lactated Ringer&#x02019;s solution was administered <italic toggle="yes">i.v.</italic> during the operation at a rate of 10 mL/kg/min. Vital signs (ECG, pulse oximetry, capnography, arterial blood pressure) were monitored, and an active warming method was applied throughout the procedure. The antibiotic cefazolin (22 mg/kg <italic toggle="yes">i.v.</italic>) was applied prophylactically every 90 min during surgery only. An intercostal thoracotomy was performed in the eighth intercostal space on the right side. A methylene blue solution was applied to the left hind leg to visualize the thoracic duct and to begin lymph aspiration over the next 4&#x02013;6 h. The volume of the lymph collected was replaced with 0.9% NaCl. At the end of the procedure, the thoracic duct was ligated, and the intercostal thoracotomy incision was closed. The health status of the animals was monitored at 6 h intervals post-operatively, and additional analgesia was administered as required. It was provided by a fentanyl patch (75 &#x003bc;g/kg <italic toggle="yes">s.c.</italic>) and the use of the non-steroidal anti-inflammatory drug meloxicam (0.1 mg/kg <italic toggle="yes">s.c.</italic>) for 5 days. A standardized pain scale was used to assess the severity of pain, suffering or distress.</p></sec><sec id="sec2dot6-pharmaceutics-17-00212"><title>2.6. Venom and Antivenom Application</title><p><italic toggle="yes">V. ammodytes</italic> venom solution was administered <italic toggle="yes">s.c.</italic> into the interdigital space of the left hind limb of each sheep. Venom was injected at a dose of 20 mg, which is a typical quantity yielded in milking of a mature snake and contained 1849 LD<sub>50</sub> doses as determined by the lethal toxicity assay [<xref rid="B54-pharmaceutics-17-00212" ref-type="bibr">54</xref>]. &#x0201c;Zagreb&#x0201d; antivenom was administered 132 min after venom-induced envenoming at a dose of 400 mg, which was found to be sufficient to neutralize 1947 LD<sub>50</sub> doses of <italic toggle="yes">V. ammodytes</italic> venom as determined by the lethal toxicity neutralization assay.</p></sec><sec id="sec2dot7-pharmaceutics-17-00212"><title>2.7. Lymph Samples</title><p>Lymph samples were collected by external drainage from the thoracic duct after surgery. Lymph was continuously aspirated over 4&#x02013;6 h into separate 15 mL tubes that were changed every 4&#x02013;10 min, depending on the flow rate (<xref rid="pharmaceutics-17-00212-f002" ref-type="fig">Figure 2</xref>a). After volume estimation, lymph samples were centrifuged to remove clots, aliquoted, and stored at &#x02212;20 &#x000b0;C until venom, ammodytoxins (Atxs), and antivenom were measured. The lymphatic absorption of venom, Atxs and <italic toggle="yes">i.m.</italic> and <italic toggle="yes">i.v.</italic> antivenoms was monitored by measuring their concentrations in continuously collected lymph samples and expressed as cumulative absorbed doses. In each sample, it was obtained by summing the values of all previous intervals.</p></sec><sec id="sec2dot8-pharmaceutics-17-00212"><title>2.8. Blood Samples</title><p>For the pharmacokinetic study, blood samples were collected from the jugular vein into 8.5 mL serum tubes at defined time points after the insertion of an intravenous catheter (20G) and fixation with two sutures (Dafilon 3-0). After venom administration, blood was collected at closely spaced intervals for the first hour, extended to 15 min until antivenom administration at 132 min, after which the sampling intervals decreased and became progressively longer over the next 6 h (<xref rid="pharmaceutics-17-00212-f002" ref-type="fig">Figure 2</xref>b). Samples were also collected at 12, 18 and 24 h after venom application and daily for the next 13 days. The last sample collected was used for the evaluation of anti-antivenom antibodies. Centrifuged samples were frozen at &#x02212;20 &#x000b0;C until concentrations were measured. To monitor venom-induced blood disorders, blood samples of L and S groups were collected from the jugular vein in EDTA/sodium citrate tubes immediately before envenomation and at 0.5, 1, 1.5, and 2 h after envenomation, then hourly for the next 5 h, and daily for one week. They were analyzed straight away.</p></sec><sec id="sec2dot9-pharmaceutics-17-00212"><title>2.9. Quantification of V. ammodytes Venom in Lymph and Serum Samples</title><p>Venom concentrations were determined by an in-house sandwich ELISA assay by coating a microtiter plate with a rabbit antivenom IgG solution (100 &#x000b5;L/well of 5 &#x000b5;g mL<sup>&#x02212;1</sup>) in a 0.05 M carbonate buffer, pH 9.6. After overnight incubation at room temperature (RT), the plate was washed and blocked with the blocking buffer (2% (<italic toggle="yes">m</italic>/<italic toggle="yes">v</italic>) solution of bovine serum albumin (BSA) in a PBS buffer containing 0.05% (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) Tween 20) (250 &#x000b5;L/well) for 4 h at 37 &#x000b0;C. Lymph and serum samples were prepared in the incubation buffer (0.5% (<italic toggle="yes">m</italic>/<italic toggle="yes">v</italic>) BSA solution in a PBS buffer containing 0.05% (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) Tween 20) according to the expected values of their absorbances. The venom solution (<italic toggle="yes">c</italic> = 1 mg mL<sup>&#x02212;1</sup>), used as the standard, and its eight serial 1.5-fold dilutions starting from 15 ng mL<sup>&#x02212;1</sup> were prepared in an incubation buffer with the respective percentage (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) of the lymph/serum (collected prior to venom administration). All samples and standards, as well as negative controls (lymph/serum collected prior to venom administration) were added in duplicates (100 &#x003bc;L/well). After overnight incubation at RT and a thorough washing, the plate was incubated with an anti-<italic toggle="yes">V. ammodytes</italic> venom IgG solution (100 &#x000b5;L/well of 5.7 &#x000b5;g mL<sup>&#x02212;1</sup>) and then with a rabbit HRP-anti-equine IgG solution (100 &#x000b5;L/well of 4000-fold dilution). Each incubation was performed for 2 h at 37 &#x000b0;C. Washing was followed by a half-hour incubation step with an <italic toggle="yes">o</italic>-phenylenediamine (OPD) solution (0.6 mg mL<sup>&#x02212;1</sup>) in a 5.5 mM citrate-phosphate buffer, pH 5.0, with 30% (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) H<sub>2</sub>O<sub>2</sub> (0.5 &#x000b5;g mL<sup>&#x02212;1</sup> of OPD solution) (100 &#x000b5;L/well) at RT in the dark. After the addition of a 12.5% (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) H<sub>2</sub>SO<sub>4</sub> solution (50 &#x000b5;L/well), the absorbance was measured at 492 nm. To calculate the venom content, the corresponding dilution factor was multiplied by each concentration that was determined from the standard curve. The cut-off value was the mean absorbance of the lymph/serum sample collected prior to venom administration, which was analyzed in the lowest dilution used for venom-containing samples, plus three standard deviations. All samples for which the absorbance obtained in the assay was less than the cut-off value were assigned a concentration of 0 ng mL<sup>&#x02212;1</sup>.</p></sec><sec id="sec2dot10-pharmaceutics-17-00212"><title>2.10. Quantification of Atxs in Lymph and Serum Samples</title><p>Atx concentrations were determined by an in-house sandwich ELISA assay, following the same protocol as for venom, with some variations. A microtiter plate was coated with a rabbit anti-Atx IgG solution (100 &#x003bc;L/well of 5 &#x000b5;g mL<sup>&#x02212;1</sup>). Lymph and serum samples were prepared and analyzed in the same manner as for venom. The AtxA solution (<italic toggle="yes">c</italic> = 10 &#x000b5;g mL<sup>&#x02212;1</sup>) was used as the standard, and its eight serial 1.5-fold dilutions starting from 1.5 ng mL<sup>&#x02212;1</sup> were prepared in the appropriate matrix. After incubation and washing, the plate was incubated with a guinea pig anti-AtxA IgG solution (100 &#x000b5;L/well of 1.5 &#x000b5;g mL<sup>&#x02212;1</sup>) followed by a rabbit HRP-anti-guinea pig IgG solution (100 &#x000b5;L/well of 10,000-fold dilution). The final steps and calculations were performed as described in <xref rid="sec2dot9-pharmaceutics-17-00212" ref-type="sec">Section 2.9</xref>.</p></sec><sec id="sec2dot11-pharmaceutics-17-00212"><title>2.11. Quantification of Antivenom in Lymph and Serum Samples</title><p>Concentrations of the antivenom (i.e., venom-specific F(ab&#x02019;)<sub>2</sub> fragments) were determined by the in-house direct ELISA assay by coating a microtiter plate with <italic toggle="yes">V. ammodytes</italic> venom solution (100 &#x000b5;L/well of 1 &#x000b5;g mL<sup>&#x02212;1</sup>) in a 0.05 M carbonate buffer, pH 9.6. After overnight incubation at RT, the plate was washed and blocked with the blocking buffer for 2 h at 37 &#x000b0;C. Lymph and serum samples were prepared in the incubation buffer according to the expected values of their absorbances and added in duplicates (100 &#x000b5;L/well) in five serial 2-fold dilutions. &#x0201c;Zagreb&#x0201d; antivenom used as the standard was added in duplicates (100 &#x003bc;L/well) in eight serial 2-fold dilutions starting from 200 ng mL<sup>&#x02212;1</sup>. Dilutions were prepared in the incubation buffer. After overnight incubation at RT and a thorough washing, the plate was incubated with goat anti-horse F(ab&#x02019;)<sub>2</sub> IgG-HRP (100 &#x000b5;L/well of 5000-fold dilution) for 2 h at 37 &#x000b0;C. The final steps and calculations were performed as described in <xref rid="sec2dot9-pharmaceutics-17-00212" ref-type="sec">Section 2.9</xref>.</p></sec><sec id="sec2dot12-pharmaceutics-17-00212"><title>2.12. Quantification of IgGs Specific for the Antivenom&#x02019;s F(ab&#x02019;)<sub>2</sub> Fragments in Serum Samples</title><p>Concentrations of IgGs specific for the antivenom&#x02019;s F(ab&#x02019;)<sub>2</sub> fragments were determined by the in-house direct ELISA assay by coating a microtiter plate with an antivenom solution (100 &#x000b5;L/well of 1 &#x000b5;g mL<sup>&#x02212;1</sup>) in a 0.05 M carbonate buffer, pH 9.6. After overnight incubation at RT, the plate was washed and blocked with the blocking buffer for 2 h at 37 &#x000b0;C. Serum samples were prepared in the incubation buffer according to the expected values of their absorbances and added in duplicates (100 &#x000b5;L/well) in serial 2-fold dilutions. After overnight incubation at RT and a thorough washing, the plate was incubated with rabbit anti-ovine IgG-HRP (100 &#x000b5;L/well of 10,000-fold dilution) for 2 h at 37 &#x000b0;C. The final steps were performed as described in <xref rid="sec2dot9-pharmaceutics-17-00212" ref-type="sec">Section 2.9</xref>. Anti-antivenom antibodies were quantified by a parallel line assay comparing each sample to an &#x0201c;in-house standard&#x0201d;, a serum containing high levels of IgGs specific for the antivenom&#x02019;s F(ab&#x02019;)<sub>2</sub> fragments, to which 100 arbitrary units per mL (AU mL<sup>&#x02212;1</sup>) were assigned.</p></sec><sec id="sec2dot13-pharmaceutics-17-00212"><title>2.13. Hemostasis and Coagulation Tests</title><p>Platelets, leukocytes, and erythrocytes were assayed using the CELL-DYN Ruby Hematology Analyzer (Abbott, IL, USA). Platelet aggregation was measured on a Multiplate Analyzer (Roche, Mannheim, Germany). Hemostasis testing was performed using the BCS XP System (Siemens Healthineers, Erlangen, Germany). For each animal, the results were expressed as the percentage of deviation from the value estimated before venom application.</p></sec><sec id="sec2dot14-pharmaceutics-17-00212"><title>2.14. Data Analysis</title><p>Each assay was independently repeated at least three times, and the average result was used for all further calculations. The pharmacokinetic analysis of measured concentrations was performed using PKSolver add-in software (version 2.0, China Pharmaceutical University, Nanjing, China) for Microsoft Excel [<xref rid="B55-pharmaceutics-17-00212" ref-type="bibr">55</xref>]. The noncompartmental model after extravascular or intravenous constant infusion input was selected to calculate the elimination half-life (<italic toggle="yes">t</italic><sub>1/2</sub>), time to reach maximum plasma concentration (<italic toggle="yes">t</italic><sub>max</sub>), maximum plasma concentration (<italic toggle="yes">c</italic><sub>max</sub>), apparent volume of distribution during terminal phase (<italic toggle="yes">V</italic><sub>z</sub>), mean residence time (MRT), area under the plasma concentration&#x02013;time curve (AUC) and apparent total body clearance (CL). Results were expressed as the mean <italic toggle="yes">&#x000b1;</italic> standard error (SE) or median (range between lower and upper percentiles), unless otherwise noted. The area under the lymph mass&#x02013;time curve was determined using Prism software (version 9.0, GraphPad Software Inc., San Diego, CA, USA). Comparisons between the <italic toggle="yes">i.m.</italic> and <italic toggle="yes">i.v.</italic> groups were evaluated by U-test at a significance level of <italic toggle="yes">p</italic> &#x0003c; 0.05, also using Prism software.</p></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-17-00212"><title>3. Results</title><sec id="sec3dot1-pharmaceutics-17-00212"><title>3.1. Lymphatic System</title><sec id="sec3dot1dot1-pharmaceutics-17-00212"><title>3.1.1. Antivenom</title><p>The lymphatic absorption of <italic toggle="yes">i.m.</italic> and <italic toggle="yes">i.v.</italic> antivenoms was monitored by measuring their concentrations (<xref rid="app1-pharmaceutics-17-00212" ref-type="app">Tables S1 and S2</xref>). When comparing the L<italic toggle="yes"><sub>i.m.</sub></italic> and L<italic toggle="yes"><sub>i.v.</sub></italic> groups, both the rate of absorption of <italic toggle="yes">i.m.</italic> antivenom (3.9 &#x000b1; 1.9 mg h<sup>&#x02212;1</sup>) and its total amount reaching the lymph during a sampling period (AUC<sub>0-<italic toggle="yes">t</italic></sub>) (25.7 &#x000b1; 14.9 mg &#x02219; h) appeared to be generally higher than for <italic toggle="yes">i.v.</italic> antivenom (<xref rid="pharmaceutics-17-00212-f003" ref-type="fig">Figure 3</xref>a, <xref rid="app1-pharmaceutics-17-00212" ref-type="app">Table S3</xref>). The rate of absorption of <italic toggle="yes">i.v.</italic> antivenom was 1.5 &#x000b1; 0.3 mg h<sup>&#x02212;1</sup>. Its AUC<sub>0-<italic toggle="yes">t</italic></sub> was 7.3 &#x000b1; 1.1 mg &#x02219; h. Overall, the L<italic toggle="yes"><sub>i.m.</sub></italic> group appeared to be exposed to a faster arrival of a larger dose of <italic toggle="yes">i.m.</italic> antivenom over time. However, within the L<italic toggle="yes"><sub>i.m.</sub></italic> group, a high variability in its absorption was observed. On the contrary, within the L<italic toggle="yes"><sub>i.v.</sub></italic> group, a more consistent level of <italic toggle="yes">i.v.</italic> antivenom exposure was ensured. As such, none of the differences appeared to be significant (<italic toggle="yes">p</italic> &#x0003e; 0.05), both in terms of rate and total dose.</p></sec><sec id="sec3dot1dot2-pharmaceutics-17-00212"><title>3.1.2. Venom and Atxs</title><p>The lymphatic absorption of either the whole venom or ammodytoxins (Atxs) was monitored by measuring their concentrations (<xref rid="app1-pharmaceutics-17-00212" ref-type="app">Tables S1 and S2</xref>). In the L<italic toggle="yes"><sub>i.m.</sub></italic> group, <italic toggle="yes">i.m.</italic> antivenom, even at low doses (about 500 &#x000b5;g on average), rapidly (after an average of 23 min) succeeded in complete neutralization of the venom present in the lymphatic circulation (<xref rid="pharmaceutics-17-00212-f004" ref-type="fig">Figure 4</xref>a). Atxs were completely neutralized somewhat earlier (after an average of 15 min), when <italic toggle="yes">i.m.</italic> antivenom was absorbed at an average dose of only 13 &#x000b5;g. On the contrary, in the L<italic toggle="yes"><sub>i.v.</sub></italic> group, <italic toggle="yes">i.v.</italic> antivenom-mediated neutralization of the venom and Atxs was only partial (<xref rid="pharmaceutics-17-00212-f004" ref-type="fig">Figure 4</xref>b). The rate of venom absorption (17.6 &#x000b1; 6.9 &#x000b5;g h<sup>&#x02212;1</sup> vs. 41.0 &#x000b1; 32.1 &#x000b5;g h<sup>&#x02212;1</sup>) and the total amount of venom reaching the lymph during the sampling period (AUC<sub>0-<italic toggle="yes">t</italic></sub>) (465.6.6 &#x000b1; 256.6 &#x000b5;g &#x02219; h vs. 853.8 &#x000b1; 694.6 &#x000b5;g &#x02219; h) were generally lower when the antivenom was given <italic toggle="yes">i.m.</italic> vs. <italic toggle="yes">i.v.</italic>, respectively (<xref rid="pharmaceutics-17-00212-f003" ref-type="fig">Figure 3</xref>b, <xref rid="app1-pharmaceutics-17-00212" ref-type="app">Table S3</xref>). Due to the high variability in the venom exposure levels within the L<italic toggle="yes"><sub>i.v.</sub></italic> group, the differences could not be proved as significant (<italic toggle="yes">p</italic> &#x0003e; 0.05) for any of the observed parameters. In contrast to venom, the absorption rate of Atxs and their AUC<sub>0-<italic toggle="yes">t</italic></sub> were congruent in both groups, regardless of the administration route (<xref rid="pharmaceutics-17-00212-f003" ref-type="fig">Figure 3</xref>c, <xref rid="app1-pharmaceutics-17-00212" ref-type="app">Table S3</xref>).</p></sec></sec><sec id="sec3dot2-pharmaceutics-17-00212"><title>3.2. Systemic Circulation</title><sec id="sec3dot2dot1-pharmaceutics-17-00212"><title>3.2.1. Antivenom</title><p>Antivenom concentrations (<xref rid="pharmaceutics-17-00212-f005" ref-type="fig">Figure 5</xref>, <xref rid="app1-pharmaceutics-17-00212" ref-type="app">Tables S4 and S5</xref>) were used for the determination of pharmacokinetic parameters (<xref rid="pharmaceutics-17-00212-f006" ref-type="fig">Figure 6</xref>a, <xref rid="app1-pharmaceutics-17-00212" ref-type="app">Table S6</xref>). In the systemic circulation of the S<italic toggle="yes"><sub>i.m</sub></italic><sub>.</sub> group, the maximum concentration (<italic toggle="yes">c</italic><sub>max</sub>) of antivenom was 52.3 &#x000b1; 11.6 &#x000b5;g mL<sup>&#x02212;1</sup>. In the systemic circulation of the S<italic toggle="yes"><sub>i.v</sub></italic><sub>.</sub> group, the <italic toggle="yes">c</italic><sub>max</sub> of antivenom was 214.8 &#x000b1; 36.6 &#x000b5;g mL<sup>&#x02212;1</sup>. The time required to reach it (<italic toggle="yes">t</italic><sub>max</sub>) in the S<italic toggle="yes"><sub>i.m.</sub></italic> group was 32.3 &#x000b1; 7.9 h. In the S<italic toggle="yes"><sub>i.v</sub></italic><sub>.</sub> group, the <italic toggle="yes">t</italic><sub>max</sub> was 0.6 &#x000b1; 0.2 h. Differences in the <italic toggle="yes">c</italic><sub>max</sub> and <italic toggle="yes">t</italic><sub>max</sub> proved significant. Both approaches resulted in a similar elimination half-life of the antivenom (<italic toggle="yes">t</italic><sub>1/2</sub>), as well as the total amount in the bloodstream over the duration of the measurement period (AUC<sub>0-<italic toggle="yes">t</italic></sub>), the volume of distribution (<italic toggle="yes">V</italic><sub>z</sub>), and clearance (CL). However, the mean residence time (MRT) was significantly longer after <italic toggle="yes">i.m.</italic> administration (82.6 &#x000b1; 8.2 h) than after <italic toggle="yes">i.v.</italic> administration (57.5 &#x000b1; 2.6 h).</p></sec><sec id="sec3dot2dot2-pharmaceutics-17-00212"><title>3.2.2. Venom and Atxs</title><p>The concentrations of venom and Atxs (<xref rid="pharmaceutics-17-00212-f005" ref-type="fig">Figure 5</xref>, <xref rid="app1-pharmaceutics-17-00212" ref-type="app">Tables S4 and S5</xref>) were used for the determination of pharmacokinetic parameters (<xref rid="pharmaceutics-17-00212-f006" ref-type="fig">Figure 6</xref>b,c, <xref rid="app1-pharmaceutics-17-00212" ref-type="app">Table S6</xref>). In both groups, the maximum venom concentrations (<italic toggle="yes">c</italic><sub>max</sub>) measured in serum were congruent but reached at different times (<xref rid="app1-pharmaceutics-17-00212" ref-type="app">Table S6</xref>). In the S<italic toggle="yes"><sub>i.m</sub></italic><sub>.</sub> group, the <italic toggle="yes">c</italic><sub>max</sub> was achieved either during the pre-treatment period or immediately after antivenom administration and just before neutralization of the venom, manifested by an immediate drop in its concentration to baseline (<xref rid="pharmaceutics-17-00212-f005" ref-type="fig">Figure 5</xref>a). Complete neutralization occurred 4 days post-antivenom administration, with the exception of one animal in which only two hours were required. In the S<italic toggle="yes"><sub>i.v.</sub></italic> group, the <italic toggle="yes">c</italic><sub>max</sub> of venom was achieved either during the pre-treatment period or even 2 days after antivenom administration. Namely, the initial neutralization of the venom, which occurred a few minutes post-antivenom administration, was followed by a pronounced secondary rise in its serum concentrations (<xref rid="pharmaceutics-17-00212-f005" ref-type="fig">Figure 5</xref>b). The phenomenon was also observed in the S<italic toggle="yes"><sub>i.m.</sub></italic> group but to a lesser extent (<xref rid="pharmaceutics-17-00212-f005" ref-type="fig">Figure 5</xref>a). Namely, total venom exposure during the post-treatment period was three times lower when antivenom was administered <italic toggle="yes">i.m.</italic> in comparison to that given <italic toggle="yes">i.v.</italic> (93.3 ((&#x000b5;g mL<sup>&#x02212;1</sup>) &#x02219; min) vs. 285.0 ((&#x000b5;g mL<sup>&#x02212;1</sup>) &#x02219; min). In addition, <italic toggle="yes">i.m.</italic> antivenom provided a higher volume of distribution (<italic toggle="yes">V</italic><sub>z</sub>) and clearance (CL) of the venom (<xref rid="pharmaceutics-17-00212-f006" ref-type="fig">Figure 6</xref>b, <xref rid="app1-pharmaceutics-17-00212" ref-type="app">Table S6</xref>). Congruent results were obtained when the pharmacokinetics of Atxs were followed (<xref rid="pharmaceutics-17-00212-f006" ref-type="fig">Figure 6</xref>c, <xref rid="app1-pharmaceutics-17-00212" ref-type="app">Table S6</xref>).</p></sec></sec><sec id="sec3dot3-pharmaceutics-17-00212"><title>3.3. Hematological and Coagulation Parameters</title><p>Envenoming caused a marked decrease in fibrinogen concentration, along with a reduction in platelet count and aggregation ability. The most pronounced drop in fibrinogen concentration, approximately 70% from baseline, was measured 6 h post- envenomation, while the onset of recovery was evident 5 h after antivenom treatment (<xref rid="pharmaceutics-17-00212-f007" ref-type="fig">Figure 7</xref>a). Similarly, platelet aggregation showed a substantial decline of about 50% from baseline, measured 1.5 to 2 h post-envenomation, with improvement observed within 1 h after antivenom administration (<xref rid="pharmaceutics-17-00212-f007" ref-type="fig">Figure 7</xref>b). The most pronounced drop in platelet count, aproximately 50% from baseline, was measured 2 h post-envenomation, while the onset of recovery was evident 1 h after antivenom treatment (<xref rid="pharmaceutics-17-00212-f007" ref-type="fig">Figure 7</xref>c). The time from antivenom administration to the recovery start was independent of the administration route. Also, envenoming was accompanied by ongoing leukocytosis, except for a transient decrease that occurred 4 h after envenomation (<xref rid="pharmaceutics-17-00212-f007" ref-type="fig">Figure 7</xref>d). Antivenom administration did not affect the increase in leukocyte count, regardless of the therapeutic principle. <italic toggle="yes">V. ammodytes</italic> venom had no effect on prothrombin time, activated partial thromboplastin time, D-dimer levels and red blood cell count, which remained within the physiological range throughout the entire measurement period.</p></sec><sec id="sec3dot4-pharmaceutics-17-00212"><title>3.4. Humoral Response Against Equine F(ab&#x02019;)<sub>2</sub> Fragments</title><p>The evaluation of IgGs raised against equine F(ab&#x02019;)<sub>2</sub> fragments in serum samples of the animals from the rescue study, which were collected two weeks after therapeutic intervention, was assesed. There was no significant difference in the humoral response between animals that received antivenom by the <italic toggle="yes">i.m.</italic> route and those that received it by the <italic toggle="yes">i.v.</italic> route (U test, <italic toggle="yes">p</italic> &#x0003e; 0.05) (<xref rid="pharmaceutics-17-00212-f008" ref-type="fig">Figure 8</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-pharmaceutics-17-00212"><title>4. Discussion</title><p>The majority of previous experimental investigations that attempted to clarify the pharmacokinetics of antibody-based therapeutics, including antivenoms, either alone or in combination with the corresponding venom, have been restricted to concentration level monitoring in the systemic circulation [<xref rid="B21-pharmaceutics-17-00212" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceutics-17-00212" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceutics-17-00212" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceutics-17-00212" ref-type="bibr">24</xref>]. It has only recently become clear that the lymphatic system cannot be ignored in a proper understanding of venom/antivenom interactions, given its important role in the transport of interstitial fluid and extravasated proteins [<xref rid="B44-pharmaceutics-17-00212" ref-type="bibr">44</xref>,<xref rid="B46-pharmaceutics-17-00212" ref-type="bibr">46</xref>,<xref rid="B56-pharmaceutics-17-00212" ref-type="bibr">56</xref>]. No other study, prior to the one described here, has attempted to elucidate the pros and cons of <italic toggle="yes">i.m.</italic> and <italic toggle="yes">i.v.</italic> antivenoms in a comprehensive and comparative manner, taking into account their neutralization efficacy in both relevant body compartments. In addition to filling in the missing gaps, the ability of <italic toggle="yes">i.m.</italic> and <italic toggle="yes">i.v.</italic> antivenoms to reverse blood disorders and their safety profiles were investigated, all with the aim of identifying the optimal course of action for envenoming therapy.</p><p>The absorption of <italic toggle="yes">i.m.</italic> and <italic toggle="yes">i.v.</italic> antivenoms into the lymphatic system was demonstrated, but differences were observed in the rate of absorption, the total amount reaching the lymph, and the ability to neutralize the circulating venom. The <italic toggle="yes">i.m.</italic> antivenom appeared to behave more favorably. Due to its better absorption properties, it was more successful in slowing down the arrival of the venom and, consequently, reducing the total amount reaching the lymph. More importantly, only <italic toggle="yes">i.m.</italic> antivenom ensured the complete neutralization of the lymph-absorbed venom. In another study in which antivenom was administered by the <italic toggle="yes">i.v.</italic> route, unbound venom also remained detectable in the lymph until the end of the experiment [<xref rid="B48-pharmaceutics-17-00212" ref-type="bibr">48</xref>]. The authors explained this by the fact that the <italic toggle="yes">i.v.</italic> antivenom concentrations in the lymph were lower than in the serum, having reached it as a result of extravasation from the blood, whereas the venom concentrations in the lymph exceeded those in the serum as a consequence of the absorption from the injection site, which acts as a depot for the extended delivery. So, the lymph appears to serve as a slow release compartment, prolonging venom exposure and compromising its neutralization by the <italic toggle="yes">i.v.</italic> antivenom, whose delayed entry from the blood may be a key limiting factor in reducing the systemic availability of the toxic components [<xref rid="B45-pharmaceutics-17-00212" ref-type="bibr">45</xref>]. This is consistent with our observation that the venom persisted in the lymph even after administration of the <italic toggle="yes">i.v.</italic> antivenom, emphasizing the importance of its interrupted absorption achieved with the <italic toggle="yes">i.m.</italic> antivenom. Our findings highlight the pronounced lymphatic mismatch between venom and <italic toggle="yes">i.v.</italic> antivenom, with <italic toggle="yes">i.m.</italic> administration providing more efficient venom clearance from the lymph.</p><p>The number of studies directly comparing the effects of <italic toggle="yes">i.v.</italic> and <italic toggle="yes">i.m.</italic> antivenoms on the pharmacokinetic profile of the venom in the systemic circulation is limited. Furthermore, differences in venom/antivenom interplay observed not only between animals and humans but also between animal models chosen according to the focus of the research and the type of snake venom [<xref rid="B57-pharmaceutics-17-00212" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceutics-17-00212" ref-type="bibr">58</xref>] make it difficult to draw straightforward conclusions. All this impairs a comprehensive understanding of the venom behavior associated with different routes of antivenom administration, which can be a significant drawback in optimizing the therapeutic protocol. Our study aimed to provide all possible data that could be calculated using non-compartmental analysis. The consistency of the elimination half-life of <italic toggle="yes">i.m.</italic> and <italic toggle="yes">i.v.</italic> antivenoms was demonstrated, confirming previous results [<xref rid="B21-pharmaceutics-17-00212" ref-type="bibr">21</xref>,<xref rid="B23-pharmaceutics-17-00212" ref-type="bibr">23</xref>]. However, <italic toggle="yes">i.m.</italic> antivenom appears to result in a higher volume of distribution of the venom, indicating a greater propensity for toxins to leave the systemic circulation and enter the extravascular compartment, potentially reducing the efficacy of the drug [<xref rid="B59-pharmaceutics-17-00212" ref-type="bibr">59</xref>], as it struggles to neutralize target components already distributed in the surrounding tissues [<xref rid="B60-pharmaceutics-17-00212" ref-type="bibr">60</xref>]. On the other hand, <italic toggle="yes">i.m.</italic> antivenom also appears to provide a higher clearance of the venom, as another important pharmacokinetic parameter representing the efficiency of the irreversible elimination of a drug. It is important to note that both the volume of distribution and clearance are correlated and together influence the elimination half-life of the venom [<xref rid="B59-pharmaceutics-17-00212" ref-type="bibr">59</xref>]. A larger volume of distribution will typically result in a longer elimination half-life by sequestering the drug in tissues away from the bloodstream. On the other hand, a higher clearance rate accelerates its removal from the systemic circulation, thereby shortening the elimination half-life. As shown in our study, these opposing effects may cancel each other out so that the venom with a higher volume of distribution and clearance, such as after <italic toggle="yes">i.m.</italic> administration of the antivenom, may have an elimination half-life comparable to that of the venom with a lower volume of distribution and clearance, such as after <italic toggle="yes">i.v.</italic> administration of the antivenom. Therefore, it is the interaction between these two parameters, rather than their individual values, that is critical in assessing the elimination half-life. The total amount of antivenom in the bloodstream during the measurement period appeared to be comparable for both administration routes. Although our finding is not in agreement with previous ones [<xref rid="B21-pharmaceutics-17-00212" ref-type="bibr">21</xref>,<xref rid="B23-pharmaceutics-17-00212" ref-type="bibr">23</xref>,<xref rid="B30-pharmaceutics-17-00212" ref-type="bibr">30</xref>], it can be explained by the slow, but sustained release of <italic toggle="yes">i.m.</italic> F(ab&#x02019;)<sub>2</sub> fragments from the injection site [<xref rid="B61-pharmaceutics-17-00212" ref-type="bibr">61</xref>,<xref rid="B62-pharmaceutics-17-00212" ref-type="bibr">62</xref>], leading to drug accumulation and resulting in similar systemic exposure as after <italic toggle="yes">i.v.</italic> administration. A sufficiently long measurement time may be required for the effect to appear. Furthermore, pharmacokinetic differences were observed in the maximum plasma concentration and the time required to reach it. When the antivenom was administered by the <italic toggle="yes">i.m.</italic> route, the <italic toggle="yes">c</italic><sub>max</sub> was significantly lower, and the <italic toggle="yes">t</italic><sub>max</sub> was significantly longer, extending to 1.3 days, which is in line with other reports showing that it can occur even up to two days post-treatment [<xref rid="B21-pharmaceutics-17-00212" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceutics-17-00212" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceutics-17-00212" ref-type="bibr">23</xref>,<xref rid="B62-pharmaceutics-17-00212" ref-type="bibr">62</xref>]. Described delay has been attributed to the prolonged arrival of the antivenom from the muscle tissue [<xref rid="B40-pharmaceutics-17-00212" ref-type="bibr">40</xref>,<xref rid="B62-pharmaceutics-17-00212" ref-type="bibr">62</xref>]. Despite the slower absorption, <italic toggle="yes">i.m.</italic> antivenom offers an advantage in situations where a sustained release and prolonged maintenance of its levels is required, such as in the treatment of viper envenomation, where the initial entry of the toxins from the <italic toggle="yes">s.c.</italic> tissue surrounding the bite site is followed by their continuous release for up to 3 days [<xref rid="B29-pharmaceutics-17-00212" ref-type="bibr">29</xref>]. As <italic toggle="yes">i.m.</italic> antivenom provides ongoing protection, recurrent envenomation is likely to be less common [<xref rid="B63-pharmaceutics-17-00212" ref-type="bibr">63</xref>], which is also supported by our results. Specifically, the reappearance of the venom in the systemic circulation was much less pronounced when antivenom was administered by the <italic toggle="yes">i.m.</italic> route compared to the <italic toggle="yes">i.v.</italic> route, as clearly indicated by the three times lower total exposure measured during the post-treatment period. This may be due to the presence of a venom reservoir in the local tissues and lymph, whose flux exceeds the binding capacity of the <italic toggle="yes">i.v.</italic> antivenom as it begins to be cleared from the systemic circulation. <italic toggle="yes">I.m.</italic> administration proved effective in maintaining lower blood venom levels over time, most likely due to the steady increase in antivenom concentrations [<xref rid="B64-pharmaceutics-17-00212" ref-type="bibr">64</xref>]. <italic toggle="yes">I.v.</italic> administration resulted in a rapid drop in venom blood levels, which may be useful in the cases of acute envenomation. However, the effect was transient, and there was a marked rebound in venom concentrations, probably due to re-circulation of the toxins stored in the peripheral tissues or the lymphatic system into the bloodstream [<xref rid="B65-pharmaceutics-17-00212" ref-type="bibr">65</xref>] or due to premature elimination of the antivenom [<xref rid="B40-pharmaceutics-17-00212" ref-type="bibr">40</xref>]. The beneficial effect of the <italic toggle="yes">i.m.</italic> antivenom on the removal of the venom from the systemic circulation may be supported by its longer mean residence time, a phenomenon already reported [<xref rid="B62-pharmaceutics-17-00212" ref-type="bibr">62</xref>,<xref rid="B66-pharmaceutics-17-00212" ref-type="bibr">66</xref>], as it allows a prolonged therapeutic effect of the drug due to the circulation through organ tissues [<xref rid="B28-pharmaceutics-17-00212" ref-type="bibr">28</xref>].</p><p>The immune system requires 1&#x02013;2 weeks after antivenom administration to recognize the heterologous equine antibodies as foreign and to mount an IgG-mediated antibody response that can lead to late adverse reactions, such as a type III hypersensitivity phenomenon associated with serum sickness that appears as a consequence of the formation of immune complexes [<xref rid="B67-pharmaceutics-17-00212" ref-type="bibr">67</xref>,<xref rid="B68-pharmaceutics-17-00212" ref-type="bibr">68</xref>]. However, the presence of anti-antivenom antibodies is not sufficient for the late adverse reactions to occur [<xref rid="B69-pharmaceutics-17-00212" ref-type="bibr">69</xref>]. The incidence of serum sickness seems to depend on the total load of foreign protein administered and the format of the antivenom preparation [<xref rid="B70-pharmaceutics-17-00212" ref-type="bibr">70</xref>]. However, as the low immunogenicity of the drug is preferable to improve product safety, our goal was to investigate the effect of administration routes on the humoral response to equine F(ab&#x02019;)<sub>2</sub> fragments between animals receiving <italic toggle="yes">i.m.</italic> antivenom and those receiving <italic toggle="yes">i.v.</italic> antivenom. No significant difference was observed, as described [<xref rid="B71-pharmaceutics-17-00212" ref-type="bibr">71</xref>]; thus, neither route was favored from a safety perspective. This can be explained by the overall low immunogenicity of F(ab&#x02019;)<sub>2</sub> fragments, which provides a solid basis for understanding why the route of administration does not significantly alter the immune response when using this type of antibody format. However, the initial evaluation is not sufficient for a definitive comparison, particularly when applied to other, more immunoreactive antivenoms. The slow release of <italic toggle="yes">i.m.</italic> antivenom may have additional safety implications that should be studied in more detail to understand the wider application.</p><p>All sheep exhibited clear evidence of envenomation almost immediately after injection of the venom. Hypofibrinogenemia, thrombocytopenia associated with reduced platelet aggregation and leukocytosis developed progressively over time. Congruent clinical signs and symptoms were often observed in human victims of the <italic toggle="yes">V. ammodytes</italic> bite [<xref rid="B12-pharmaceutics-17-00212" ref-type="bibr">12</xref>,<xref rid="B40-pharmaceutics-17-00212" ref-type="bibr">40</xref>,<xref rid="B72-pharmaceutics-17-00212" ref-type="bibr">72</xref>,<xref rid="B73-pharmaceutics-17-00212" ref-type="bibr">73</xref>,<xref rid="B74-pharmaceutics-17-00212" ref-type="bibr">74</xref>,<xref rid="B75-pharmaceutics-17-00212" ref-type="bibr">75</xref>,<xref rid="B76-pharmaceutics-17-00212" ref-type="bibr">76</xref>,<xref rid="B77-pharmaceutics-17-00212" ref-type="bibr">77</xref>]. The antivenom had a positive effect on the outcome, as the normal values of the laboratory results were quickly restored after its administration, confirming the therapeutic efficacy regardless of the route. Only the leukocyte count was not reversed by the antivenom, as previously reported [<xref rid="B72-pharmaceutics-17-00212" ref-type="bibr">72</xref>,<xref rid="B77-pharmaceutics-17-00212" ref-type="bibr">77</xref>], and continued to increase possibly due to the inflammatory process and cytokine production [<xref rid="B78-pharmaceutics-17-00212" ref-type="bibr">78</xref>] triggered by severe local tissue damage, one of the most frequently recorded effects of <italic toggle="yes">V. ammodytes</italic> envenomation [<xref rid="B59-pharmaceutics-17-00212" ref-type="bibr">59</xref>]. According to Hsu et al., an elevated value of this parameter may contribute to the early diagnosis of compartment syndrome [<xref rid="B79-pharmaceutics-17-00212" ref-type="bibr">79</xref>].</p></sec><sec sec-type="conclusions" id="sec5-pharmaceutics-17-00212"><title>5. Conclusions</title><p>Our study demonstrated for the first time not only the neutralizing effect of <italic toggle="yes">i.m.</italic> antivenom in the lymphatic system but also allowed us to compare the impact of <italic toggle="yes">i.m.</italic> and <italic toggle="yes">i.v.</italic> routes on venom depletion in both relevant body compartments where interaction with circulating toxins occurs. These results are in agreement with Kurtovi&#x00107; et al. [<xref rid="B40-pharmaceutics-17-00212" ref-type="bibr">40</xref>], who highlighted the potential of <italic toggle="yes">i.m.</italic> antivenom to provide early therapeutic levels, particularly in emergency situations, without the need for additional doses to fully resolve all clinical signs. This study has disproved the negative connotation associated with <italic toggle="yes">i.m.</italic> administration, proving that it is an equally good concept from the standpoint of removing the venom from both the lymph and blood, as well as normalizing hematologic abnormalities commonly observed in viperid envenomations. However, it should be noted that its efficacy is currently only applicable to <italic toggle="yes">V. ammodytes</italic> venom and not to snake venoms in general. Also, awareness of the limited usefulness of <italic toggle="yes">i.m.</italic> antivenom should be cautioned, especially in light of previous work in mice [<xref rid="B28-pharmaceutics-17-00212" ref-type="bibr">28</xref>]. Future studies are needed to draw firm conclusions. Finally, the pharmacokinetic properties of different venom/antivenom combinations vary considerably, mainly due to differences in molecular size. A recent computational model provided a theoretical framework to understand their impact on the behavior of these substances in the body, as well as the efficacy and timing of treatment [<xref rid="B80-pharmaceutics-17-00212" ref-type="bibr">80</xref>]. These pharmacokinetic differences should be considered beyond the specific venom/antivenom combination that we studied, with broader implications for other venom types and antivenom formats.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceutics-17-00212"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xlink:href="https://www.mdpi.com/article/10.3390/pharmaceutics17020212/s1">https://www.mdpi.com/article/10.3390/pharmaceutics17020212/s1</uri>, Table S1: Concentrations of venom, Atx and antivenom measured in the lymph samples of envenomed and <italic toggle="yes">i.m.</italic>-treated sheep; Table S2: Concentrations of venom, Atx and antivenom measured in the lymph samples of envenomed and <italic toggle="yes">i.v.</italic>-treated sheep; Table S3: Lymphatic absorption of <italic toggle="yes">i.m.</italic> and <italic toggle="yes">i.v.</italic> antivenoms and its influence on the rate of absorption of <italic toggle="yes">s.c.</italic> injected venom and ammodytoxins (Atxs), as well as on their total amount reaching the lymph during a sampling period (AUC<sub>0-<italic toggle="yes">t</italic></sub>); Table S4: Concentrations of venom, Atx and antivenom measured in the serum samples of envenomed and <italic toggle="yes">i.m.</italic>-treated sheep; Table S5: Concentrations of venom, Atx and antivenom measured in the serum samples of envenomed and <italic toggle="yes">i.v.</italic>-treated sheep; and Table S6: Pharmacokinetic parameters of <italic toggle="yes">s.c.</italic> applied venom (<italic toggle="yes">m</italic> = 20 mg) and ammodytoxins (Atxs), as well as <italic toggle="yes">i.m.</italic> (S<italic toggle="yes"><sub>i.m.</sub></italic> group) and <italic toggle="yes">i.v.</italic> (S<italic toggle="yes"><sub>i.v.</sub></italic> group) antivenoms (<italic toggle="yes">m</italic> = 400 mg) in the systemic circulation.</p><supplementary-material id="pharmaceutics-17-00212-s001" position="float" content-type="local-data"><media xlink:href="pharmaceutics-17-00212-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization: T.K., M.L.B. and B.H.; methodology: T.K., M.L.B., D.V., A.S., J.G.H., M.T., A.H. and B.H.; formal analysis: E.G., S.M.L. and T.K.; investigation: E.G., S.M.L., T.K., M.L.B., D.V., A.S., J.G.H., M.T. and A.H.; resources: T.K.; data curation: E.G., S.M.L. and T.K.; writing&#x02014;original draft: E.G. and T.K.; writing&#x02014;review and editing: T.K., B.H., S.M.L. and M.L.B.; visualization: T.K.; supervision: T.K.; project administration: T.K.; funding acquisition: T.K. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The animal study protocol was approved by the Croatian Ministry of Agriculture, Veterinary and Food Safety Directorate (UP/I-322-01/20-01/62, permission no. 525-10/1338-21-5). The approval was based on the positive opinion of the National Ethical Committee (EP 315/2021). This study was conducted in accordance with the EU Directive 2010/63/EU on the protection of animals used for scientific purposes.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article/<xref rid="app1-pharmaceutics-17-00212" ref-type="app">Supplementary Material</xref>. Further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00212"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Warrell</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Venomous Bites, Stings, and Poisoning: An Update</article-title><source>Infect. Dis. Clin. N. Am.</source><year>2019</year><volume>33</volume><fpage>17</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2018.10.001</pub-id><pub-id pub-id-type="pmid">30712761</pub-id>
</element-citation></ref><ref id="B2-pharmaceutics-17-00212"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guti&#x000e9;rrez</surname><given-names>J.M.</given-names></name>
<name><surname>Calvete</surname><given-names>J.J.</given-names></name>
<name><surname>Habib</surname><given-names>A.G.</given-names></name>
<name><surname>Harrison</surname><given-names>R.A.</given-names></name>
<name><surname>Williams</surname><given-names>D.J.</given-names></name>
<name><surname>Warrell</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Snakebite Envenoming</article-title><source>Nat. Rev. Dis. Prim.</source><year>2017</year><volume>3</volume><fpage>17063</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2017.63</pub-id><pub-id pub-id-type="pmid">28905944</pub-id>
</element-citation></ref><ref id="B3-pharmaceutics-17-00212"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Chippaux</surname><given-names>J.P.</given-names></name>
<name><surname>Stock</surname><given-names>R.P.</given-names></name>
<name><surname>Massougbodji</surname><given-names>A.</given-names></name>
</person-group><article-title>Antivenom Safety and Tolerance for the Strategy of Snake Envenomation Management</article-title><source>Snake Venoms</source><publisher-name>Springer</publisher-name><publisher-loc>Dordrecht, The Netherlands</publisher-loc><year>2015</year><fpage>1</fpage><lpage>16</lpage><isbn>9789400766488</isbn></element-citation></ref><ref id="B4-pharmaceutics-17-00212"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guti&#x000e9;rrez</surname><given-names>J.M.</given-names></name>
<name><surname>Le&#x000f3;n</surname><given-names>G.</given-names></name>
<name><surname>Lomonte</surname><given-names>B.</given-names></name>
<name><surname>Angulo</surname><given-names>Y.</given-names></name>
</person-group><article-title>Antivenoms for Snakebite Envenomings</article-title><source>Inflamm. Allergy-Drug Targets</source><year>2011</year><volume>10</volume><fpage>369</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.2174/187152811797200669</pub-id><pub-id pub-id-type="pmid">21745181</pub-id>
</element-citation></ref><ref id="B5-pharmaceutics-17-00212"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calmette</surname><given-names>A.</given-names></name>
</person-group><article-title>The Treatment of Animals Poisoned with Snake Venom by the Injection of Antivenomous Serum</article-title><source>Br. Med. J.</source><year>1896</year><volume>2</volume><fpage>399</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1136/bmj.2.1859.399</pub-id></element-citation></ref><ref id="B6-pharmaceutics-17-00212"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Habib</surname><given-names>A.G.</given-names></name>
<name><surname>Brown</surname><given-names>N.I.</given-names></name>
</person-group><article-title>The Snakebite Problem and Antivenom Crisis from a Health-Economic Perspective</article-title><source>Toxicon</source><year>2018</year><volume>150</volume><fpage>115</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2018.05.009</pub-id><pub-id pub-id-type="pmid">29782952</pub-id>
</element-citation></ref><ref id="B7-pharmaceutics-17-00212"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abubakar</surname><given-names>I.S.</given-names></name>
<name><surname>Abubakar</surname><given-names>S.B.</given-names></name>
<name><surname>Habib</surname><given-names>A.G.</given-names></name>
<name><surname>Nasidi</surname><given-names>A.</given-names></name>
<name><surname>Durfa</surname><given-names>N.</given-names></name>
<name><surname>Yusuf</surname><given-names>P.O.</given-names></name>
<name><surname>Larnyang</surname><given-names>S.</given-names></name>
<name><surname>Garnvwa</surname><given-names>J.</given-names></name>
<name><surname>Sokomba</surname><given-names>E.</given-names></name>
<name><surname>Salako</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Randomised Controlled Double-Blind Non-Inferiority Trial of Two Antivenoms for Saw-Scaled or Carpet Viper (<italic toggle="yes">Echis Ocellatus</italic>) Envenoming in Nigeria</article-title><source>PLoS Negl. Trop. Dis.</source><year>2010</year><volume>4</volume><elocation-id>e767</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0000767</pub-id><pub-id pub-id-type="pmid">20668549</pub-id>
</element-citation></ref><ref id="B8-pharmaceutics-17-00212"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Theakston</surname><given-names>R.D.G.</given-names></name>
<name><surname>Warrell</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Crisis in Snake Antivenom Supply for Africa</article-title><source>Lancet</source><year>2000</year><volume>356</volume><fpage>2104</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)74319-1</pub-id></element-citation></ref><ref id="B9-pharmaceutics-17-00212"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Williams</surname><given-names>D.J.</given-names></name>
<name><surname>Guti&#x000e9;rrez</surname><given-names>J.M.</given-names></name>
<name><surname>Calvete</surname><given-names>J.J.</given-names></name>
<name><surname>W&#x000fc;ster</surname><given-names>W.</given-names></name>
<name><surname>Ratanabanangkoon</surname><given-names>K.</given-names></name>
<name><surname>Paiva</surname><given-names>O.</given-names></name>
<name><surname>Brown</surname><given-names>N.I.</given-names></name>
<name><surname>Casewell</surname><given-names>N.R.</given-names></name>
<name><surname>Harrison</surname><given-names>R.A.</given-names></name>
<name><surname>Rowley</surname><given-names>P.D.</given-names></name>
<etal/>
</person-group><article-title>Ending the Drought: New Strategies for Improving the Flow of Affordable, Effective Antivenoms in Asia and Africa</article-title><source>J. Proteomics</source><year>2011</year><volume>74</volume><fpage>1735</fpage><lpage>1767</lpage><pub-id pub-id-type="doi">10.1016/j.jprot.2011.05.027</pub-id><pub-id pub-id-type="pmid">21640209</pub-id>
</element-citation></ref><ref id="B10-pharmaceutics-17-00212"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kurtovi&#x00107;</surname><given-names>T.</given-names></name>
<name><surname>Brvar</surname><given-names>M.</given-names></name>
<name><surname>Grenc</surname><given-names>D.</given-names></name>
<name><surname>Balija</surname><given-names>M.L.</given-names></name>
<name><surname>Kri&#x0017e;aj</surname><given-names>I.</given-names></name>
<name><surname>Halassy</surname><given-names>B.</given-names></name>
</person-group><article-title>A Single Dose of Viperfav<sup>TM</sup> May Be Inadequate for <italic toggle="yes">Vipera Ammodytes</italic> Snake Bite: A Case Report and Pharmacokinetic Evaluation</article-title><source>Toxins</source><year>2016</year><volume>8</volume><elocation-id>244</elocation-id><pub-id pub-id-type="doi">10.3390/toxins8080244</pub-id><pub-id pub-id-type="pmid">27548220</pub-id>
</element-citation></ref><ref id="B11-pharmaceutics-17-00212"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jollivet</surname><given-names>V.</given-names></name>
<name><surname>Hamel</surname><given-names>J.F.</given-names></name>
<name><surname>De Haro</surname><given-names>L.</given-names></name>
<name><surname>Labadie</surname><given-names>M.</given-names></name>
<name><surname>Sapori</surname><given-names>J.M.</given-names></name>
<name><surname>Cordier</surname><given-names>L.</given-names></name>
<name><surname>Villa</surname><given-names>A.</given-names></name>
<name><surname>Nisse</surname><given-names>P.</given-names></name>
<name><surname>Puskarczyk</surname><given-names>E.</given-names></name>
<name><surname>Berthelon</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>European Viper Envenomation Recorded by French Poison Control Centers: A Clinical Assessment and Management Study</article-title><source>Toxicon</source><year>2015</year><volume>108</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2015.09.039</pub-id><pub-id pub-id-type="pmid">26454165</pub-id>
</element-citation></ref><ref id="B12-pharmaceutics-17-00212"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luk&#x00161;i&#x00107;</surname><given-names>B.</given-names></name>
<name><surname>Bradari&#x00107;</surname><given-names>N.</given-names></name>
<name><surname>Prgomet</surname><given-names>S.</given-names></name>
</person-group><article-title>Venomous Snakebites in Southern Croatia</article-title><source>Coll. Antropol.</source><year>2006</year><volume>30</volume><fpage>191</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">16617597</pub-id>
</element-citation></ref><ref id="B13-pharmaceutics-17-00212"><label>13.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Snakebite Envenoming&#x02014;A Strategy for Prevention and Control</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/publications/i/item/9789241515641" ext-link-type="uri">https://www.who.int/publications/i/item/9789241515641</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-05-12">(accessed on 12 May 2023)</date-in-citation></element-citation></ref><ref id="B14-pharmaceutics-17-00212"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Williams</surname><given-names>D.</given-names></name>
<name><surname>Guti&#x000e9;rrez</surname><given-names>J.M.</given-names></name>
<name><surname>Harrison</surname><given-names>R.</given-names></name>
<name><surname>Warrell</surname><given-names>D.A.</given-names></name>
<name><surname>White</surname><given-names>J.</given-names></name>
<name><surname>Winkel</surname><given-names>K.D.</given-names></name>
<name><surname>Gopalakrishnakone</surname><given-names>P.</given-names></name>
</person-group><article-title>The Global Snake Bite Initiative: An Antidote for Snake Bite</article-title><source>Lancet</source><year>2010</year><volume>375</volume><fpage>89</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)61159-4</pub-id><pub-id pub-id-type="pmid">20109867</pub-id>
</element-citation></ref><ref id="B15-pharmaceutics-17-00212"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scherrmann</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Antibody Treatment of Toxin Poisoning Recent Advances</article-title><source>Clin. Toxicol.</source><year>1994</year><volume>32</volume><fpage>363</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.3109/15563659409011037</pub-id></element-citation></ref><ref id="B16-pharmaceutics-17-00212"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guti&#x000e9;rrez</surname><given-names>J.M.</given-names></name>
<name><surname>Solano</surname><given-names>G.</given-names></name>
<name><surname>Pla</surname><given-names>D.</given-names></name>
<name><surname>Herrera</surname><given-names>M.</given-names></name>
<name><surname>Segura</surname><given-names>&#x000c1;.</given-names></name>
<name><surname>Vargas</surname><given-names>M.</given-names></name>
<name><surname>Villalta</surname><given-names>M.</given-names></name>
<name><surname>S&#x000e1;nchez</surname><given-names>A.</given-names></name>
<name><surname>Sanz</surname><given-names>L.</given-names></name>
<name><surname>Lomonte</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Preclinical Evaluation of the Efficacy of Antivenoms for Snakebite Envenoming: State-of-the-Art and Challenges Ahead</article-title><source>Toxins</source><year>2017</year><volume>9</volume><elocation-id>163</elocation-id><pub-id pub-id-type="doi">10.3390/toxins9050163</pub-id><pub-id pub-id-type="pmid">28505100</pub-id>
</element-citation></ref><ref id="B17-pharmaceutics-17-00212"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gamulin</surname><given-names>E.</given-names></name>
<name><surname>Mateljak Luka&#x0010d;evi&#x00107;</surname><given-names>S.</given-names></name>
<name><surname>Halassy</surname><given-names>B.</given-names></name>
<name><surname>Kurtovi&#x00107;</surname><given-names>T.</given-names></name>
</person-group><article-title>Snake Antivenoms&#x02014;Toward Better Understanding of the Administration Route</article-title><source>Toxins</source><year>2023</year><volume>15</volume><elocation-id>398</elocation-id><pub-id pub-id-type="doi">10.3390/toxins15060398</pub-id><pub-id pub-id-type="pmid">37368699</pub-id>
</element-citation></ref><ref id="B18-pharmaceutics-17-00212"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lamb</surname><given-names>T.</given-names></name>
<name><surname>de Haro</surname><given-names>L.</given-names></name>
<name><surname>Lonati</surname><given-names>D.</given-names></name>
<name><surname>Brvar</surname><given-names>M.</given-names></name>
<name><surname>Eddleston</surname><given-names>M.</given-names></name>
</person-group><article-title>Antivenom for European Vipera Species Envenoming</article-title><source>Clin. Toxicol.</source><year>2017</year><volume>55</volume><fpage>557</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1080/15563650.2017.1300261</pub-id></element-citation></ref><ref id="B19-pharmaceutics-17-00212"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Regional Office for South-East Asia</article-title><source>Guidelines for the Management of Snake-Bites</source><person-group person-group-type="editor">
<name><surname>Warrell</surname><given-names>D.A.</given-names></name>
</person-group><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2010</year><isbn>978-92-9022-377-4</isbn></element-citation></ref><ref id="B20-pharmaceutics-17-00212"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><source>Guidelines for the Clinical Management of Snake Bites in the South-East Asia Region</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2005</year></element-citation></ref><ref id="B21-pharmaceutics-17-00212"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pepin</surname><given-names>S.</given-names></name>
<name><surname>Lutsch</surname><given-names>C.</given-names></name>
<name><surname>Grandgeorge</surname><given-names>M.</given-names></name>
<name><surname>Scherrmann</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Snake F(Ab&#x02019;)2 Antivenom from Hyperimmunized Horse: Pharmacokinetics Following Intravenous and Intramuscular Administrations in Rabbits</article-title><source>Pharm. Res.</source><year>1995</year><volume>12</volume><fpage>1470</fpage><lpage>1473</lpage><pub-id pub-id-type="doi">10.1023/A:1016279219619</pub-id><pub-id pub-id-type="pmid">8584483</pub-id>
</element-citation></ref><ref id="B22-pharmaceutics-17-00212"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ismail</surname><given-names>M.</given-names></name>
<name><surname>Abd-Elsalam</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Serotherapy of Scorpion Envenoming: Pharmacokinetics of Antivenoms and a Critical Assessment of Their Usefulness</article-title><source>Toxicon</source><year>1996</year><volume>34</volume><fpage>147</fpage><pub-id pub-id-type="doi">10.1016/0041-0101(96)83665-8</pub-id></element-citation></ref><ref id="B23-pharmaceutics-17-00212"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>P&#x000e9;pin-Covatta</surname><given-names>S.</given-names></name>
<name><surname>Lutsch</surname><given-names>C.</given-names></name>
<name><surname>Grandgeorge</surname><given-names>M.</given-names></name>
<name><surname>Lang</surname><given-names>J.</given-names></name>
<name><surname>Scherrmann</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Immunoreactivity and Pharmacokinetics of Horse Anti-Scorpion Venom F(Ab&#x02019;)2-Scorpion Venom Interactions</article-title><source>Toxicol. Appl. Pharmacol.</source><year>1996</year><volume>141</volume><fpage>272</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1016/S0041-008X(96)80033-0</pub-id><pub-id pub-id-type="pmid">8917700</pub-id>
</element-citation></ref><ref id="B24-pharmaceutics-17-00212"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rivi&#x000e8;re</surname><given-names>G.</given-names></name>
<name><surname>Choumet</surname><given-names>V.</given-names></name>
<name><surname>Saliou</surname><given-names>B.</given-names></name>
<name><surname>Debray</surname><given-names>M.</given-names></name>
<name><surname>Bon</surname><given-names>C.</given-names></name>
</person-group><article-title>Absorption and Elimination of Viper Venom after Antivenom Administration</article-title><source>J. Pharmacol. Exp. Ther.</source><year>1998</year><volume>285</volume><fpage>490</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1016/S0022-3565(24)37451-8</pub-id><pub-id pub-id-type="pmid">9580588</pub-id>
</element-citation></ref><ref id="B25-pharmaceutics-17-00212"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krifi</surname><given-names>M.N.</given-names></name>
<name><surname>Amri</surname><given-names>F.</given-names></name>
<name><surname>Kharrat</surname><given-names>H.</given-names></name>
<name><surname>El Ayeb</surname><given-names>M.</given-names></name>
</person-group><article-title>Evaluation of Antivenom Therapy in Children Severely Envenomed by <italic toggle="yes">Androctonus Australis Garzonii</italic> (Aag) and <italic toggle="yes">Buthus Occitanus Tunetanus</italic> (Bot) Scorpions</article-title><source>Toxicon</source><year>1999</year><volume>37</volume><fpage>1627</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.1016/S0041-0101(99)00079-3</pub-id><pub-id pub-id-type="pmid">10482396</pub-id>
</element-citation></ref><ref id="B26-pharmaceutics-17-00212"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghalim</surname><given-names>N.</given-names></name>
<name><surname>El-Hafny</surname><given-names>B.</given-names></name>
<name><surname>Sebti</surname><given-names>F.</given-names></name>
<name><surname>Heikel</surname><given-names>J.</given-names></name>
<name><surname>Lazar</surname><given-names>N.</given-names></name>
<name><surname>Moustanir</surname><given-names>R.</given-names></name>
<name><surname>Benslimane</surname><given-names>A.</given-names></name>
</person-group><article-title>Scorpion Envenomation and Serotherapy in Morocco</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2000</year><volume>62</volume><fpage>277</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2000.62.277</pub-id><pub-id pub-id-type="pmid">10813485</pub-id>
</element-citation></ref><ref id="B27-pharmaceutics-17-00212"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Isbister</surname><given-names>G.K.</given-names></name>
<name><surname>O&#x02019;Leary</surname><given-names>M.</given-names></name>
<name><surname>Miller</surname><given-names>M.</given-names></name>
<name><surname>Brown</surname><given-names>S.G.A.</given-names></name>
<name><surname>Ramasamy</surname><given-names>S.</given-names></name>
<name><surname>James</surname><given-names>R.</given-names></name>
<name><surname>Schneider</surname><given-names>J.S.</given-names></name>
</person-group><article-title>A Comparison of Serum Antivenom Concentrations after Intravenous and Intramuscular Administration of Redback (Widow) Spider Antivenom</article-title><source>Br. J. Clin. Pharmacol.</source><year>2007</year><volume>65</volume><fpage>139</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2007.03004.x</pub-id><pub-id pub-id-type="pmid">18171334</pub-id>
</element-citation></ref><ref id="B28-pharmaceutics-17-00212"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guti&#x000e9;rrez</surname><given-names>J.M.</given-names></name>
<name><surname>Le&#x000f3;n</surname><given-names>G.</given-names></name>
<name><surname>Lomonte</surname><given-names>B.</given-names></name>
</person-group><article-title>Pharmacokinetic-Pharmacodynamic Relationships of Immunoglobulin Therapy for Envenomation</article-title><source>Clin. Pharmacokinet.</source><year>2003</year><volume>42</volume><fpage>721</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.2165/00003088-200342080-00002</pub-id><pub-id pub-id-type="pmid">12846594</pub-id>
</element-citation></ref><ref id="B29-pharmaceutics-17-00212"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Audebert</surname><given-names>F.</given-names></name>
<name><surname>Urtizberea</surname><given-names>M.</given-names></name>
<name><surname>Sabouraud</surname><given-names>A.</given-names></name>
<name><surname>Scherrmann</surname><given-names>J.M.</given-names></name>
<name><surname>Bon</surname><given-names>C.</given-names></name>
</person-group><article-title>Pharmacokinetics of <italic toggle="yes">Vipera Aspis</italic> Venom after Experimental Envenomation in Rabbits</article-title><source>J. Pharmacol. Exp. Ther.</source><year>1994</year><volume>268</volume><fpage>1512</fpage><lpage>1517</lpage><pub-id pub-id-type="doi">10.1016/S0022-3565(25)38643-X</pub-id><pub-id pub-id-type="pmid">8138962</pub-id>
</element-citation></ref><ref id="B30-pharmaceutics-17-00212"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rivi&#x000e8;re</surname><given-names>G.</given-names></name>
<name><surname>Choumet</surname><given-names>V.</given-names></name>
<name><surname>Audebert</surname><given-names>F.</given-names></name>
<name><surname>Sabouraud</surname><given-names>A.</given-names></name>
<name><surname>Debray</surname><given-names>M.</given-names></name>
<name><surname>Scherrmann</surname><given-names>J.M.</given-names></name>
<name><surname>Bon</surname><given-names>C.</given-names></name>
</person-group><article-title>Effect of Antivenom on Venom Pharmacokinetics in Experimentally Envenomed Rabbits: Toward an Optimization of Antivenom Therapy</article-title><source>J. Pharmacol. Exp. Ther.</source><year>1997</year><volume>281</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S0022-3565(24)36597-8</pub-id><pub-id pub-id-type="pmid">9103473</pub-id>
</element-citation></ref><ref id="B31-pharmaceutics-17-00212"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chippaux</surname><given-names>J.P.</given-names></name>
<name><surname>Massougbodji</surname><given-names>A.</given-names></name>
<name><surname>Stock</surname><given-names>R.P.</given-names></name>
<name><surname>Alagon</surname><given-names>A.</given-names></name>
<name><surname>Fassinou</surname><given-names>E.</given-names></name>
<name><surname>Ndamadjo</surname><given-names>A.</given-names></name>
<name><surname>Soglo</surname><given-names>R.</given-names></name>
<name><surname>Tamou</surname><given-names>B.E.</given-names></name>
<name><surname>Mama</surname><given-names>A.B.</given-names></name>
<name><surname>Nguemezi</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Clinical Trial of an F(Ab&#x02032;)2 Polyvalent Equine Antivenom for African Snake Bites in Benin</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2007</year><volume>77</volume><fpage>538</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2007.77.538</pub-id><pub-id pub-id-type="pmid">17827375</pub-id>
</element-citation></ref><ref id="B32-pharmaceutics-17-00212"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boels</surname><given-names>D.</given-names></name>
<name><surname>Hamel</surname><given-names>J.F.</given-names></name>
<name><surname>Deguigne</surname><given-names>M.B.</given-names></name>
<name><surname>Harry</surname><given-names>P.</given-names></name>
</person-group><article-title>European Viper Envenomings: Assessment of Viperfav<sup>TM</sup> and Other Symptomatic Treatments</article-title><source>Clin. Toxicol.</source><year>2012</year><volume>50</volume><fpage>189</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.3109/15563650.2012.660695</pub-id></element-citation></ref><ref id="B33-pharmaceutics-17-00212"><label>33.</label><element-citation publication-type="gov"><article-title>Bula Com Informa&#x000e7;&#x000f5;es Ao Paciente&#x02014;Soro Antibotr&#x000f3;pico (Pentavalente) e Antilaqu&#x000e9;tico</article-title><comment>Available online: <ext-link xlink:href="http://www.funed.mg.gov.br/wp-content/uploads/2018/11/1.-Bula-de-soro-antibotr&#x000f3;pico-pentavalente-e-antilaqu&#x000e9;tico-para-o-Paciente.pdf" ext-link-type="uri">http://www.funed.mg.gov.br/wp-content/uploads/2018/11/1.-Bula-de-soro-antibotr&#x000f3;pico-pentavalente-e-antilaqu&#x000e9;tico-para-o-Paciente.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-05-11">(accessed on 11 May 2023)</date-in-citation></element-citation></ref><ref id="B34-pharmaceutics-17-00212"><label>34.</label><element-citation publication-type="gov"><article-title>Bula Com Informa&#x000e7;&#x000f5;es Ao Paciente&#x02014;Soro Antielap&#x000ed;dico (Bivalente)</article-title><comment>Available online: <ext-link xlink:href="http://www.funed.mg.gov.br/wp-content/uploads/2018/11/1.-Bula-de-soro-antielap&#x000ed;dico-bivalente-para-o-Paciente.pdf" ext-link-type="uri">http://www.funed.mg.gov.br/wp-content/uploads/2018/11/1.-Bula-de-soro-antielap&#x000ed;dico-bivalente-para-o-Paciente.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-05-11">(accessed on 11 May 2023)</date-in-citation></element-citation></ref><ref id="B35-pharmaceutics-17-00212"><label>35.</label><element-citation publication-type="gov"><article-title>Bula Com Informa&#x000e7;&#x000f5;es Ao Paciente&#x02014;Soro Anticrot&#x000e1;lico</article-title><comment>Available online: <ext-link xlink:href="http://www.funed.mg.gov.br/wp-content/uploads/2020/04/Bula-do-soro-anticrot&#x000e1;lico-para-o-paciente-2020.pdf" ext-link-type="uri">http://www.funed.mg.gov.br/wp-content/uploads/2020/04/Bula-do-soro-anticrot&#x000e1;lico-para-o-paciente-2020.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-05-11">(accessed on 11 May 2023)</date-in-citation></element-citation></ref><ref id="B36-pharmaceutics-17-00212"><label>36.</label><element-citation publication-type="webpage"><article-title>Viekvin&#x02014;Viper Venom Antiserum (Equine)</article-title><comment>Available online: <ext-link xlink:href="http://www.torlakinstitut.com/pdf/Viekvin-en.pdf" ext-link-type="uri">http://www.torlakinstitut.com/pdf/Viekvin-en.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-05-11">(accessed on 11 May 2023)</date-in-citation></element-citation></ref><ref id="B37-pharmaceutics-17-00212"><label>37.</label><element-citation publication-type="webpage"><article-title>Vetal Serum&#x02014;&#x000dc;r&#x000fc;nlerimiz</article-title><comment>Available online: <ext-link xlink:href="http://www.vetalserum.com.tr/en/urunler/polisera-snake-antiserum" ext-link-type="uri">http://www.vetalserum.com.tr/en/urunler/polisera-snake-antiserum</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-05-11">(accessed on 11 May 2023)</date-in-citation></element-citation></ref><ref id="B38-pharmaceutics-17-00212"><label>38.</label><element-citation publication-type="webpage"><article-title>Viper Venom Antitoxin</article-title><comment>Available online: <ext-link xlink:href="https://www.biodrug.sk/docs/en_viper_venom.pdf" ext-link-type="uri">https://www.biodrug.sk/docs/en_viper_venom.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-05-11">(accessed on 11 May 2023)</date-in-citation></element-citation></ref><ref id="B39-pharmaceutics-17-00212"><label>39.</label><element-citation publication-type="confproc"><person-group person-group-type="author">
<name><surname>Win</surname><given-names>A.</given-names></name>
</person-group><article-title>Intramuscular Antivenom Administration as an Effective First-Aid Measure in Management of Snakebites</article-title><source>Proceedings of the Management of Snakebite and Research&#x02014;Report and Working Papers of a Seminar Yangon</source><conf-loc>Yangon, Myanmar</conf-loc><conf-date>11&#x02013;12 December 2001</conf-date><fpage>29</fpage><lpage>33</lpage></element-citation></ref><ref id="B40-pharmaceutics-17-00212"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kurtovi&#x00107;</surname><given-names>T.</given-names></name>
<name><surname>Karabuva</surname><given-names>S.</given-names></name>
<name><surname>Grenc</surname><given-names>D.</given-names></name>
<name><surname>Borak</surname><given-names>M.D.</given-names></name>
<name><surname>Kri&#x0017e;aj</surname><given-names>I.</given-names></name>
<name><surname>Luk&#x00161;i&#x00107;</surname><given-names>B.</given-names></name>
<name><surname>Halassy</surname><given-names>B.</given-names></name>
<name><surname>Brvar</surname><given-names>M.</given-names></name>
</person-group><article-title>Intravenous <italic toggle="yes">Vipera Berus</italic> Venom-Specific Fab Fragments and Intramuscular <italic toggle="yes">Vipera Ammodytes</italic> Venom-Specific F(Ab&#x02019;)2 Fragments in <italic toggle="yes">Vipera Ammodytes</italic>-Envenomed Patients</article-title><source>Toxins</source><year>2021</year><volume>13</volume><elocation-id>279</elocation-id><pub-id pub-id-type="doi">10.3390/toxins13040279</pub-id><pub-id pub-id-type="pmid">33919927</pub-id>
</element-citation></ref><ref id="B41-pharmaceutics-17-00212"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garkowski</surname><given-names>A.</given-names></name>
<name><surname>Czupryna</surname><given-names>P.</given-names></name>
<name><surname>Zajkowska</surname><given-names>A.</given-names></name>
<name><surname>Pancewicz</surname><given-names>S.</given-names></name>
<name><surname>Moniuszko</surname><given-names>A.</given-names></name>
<name><surname>Kondrusik</surname><given-names>M.</given-names></name>
<name><surname>Grygorczuk</surname><given-names>S.</given-names></name>
<name><surname>Go&#x00141;ebicki</surname><given-names>P.</given-names></name>
<name><surname>Letmanowski</surname><given-names>M.</given-names></name>
<name><surname>Zajkowska</surname><given-names>J.</given-names></name>
</person-group><article-title>Vipera Berus Bites in Eastern Poland&#x02014;A Retrospective Analysis of 15 Case Studies</article-title><source>Ann. Agric. Environ. Med.</source><year>2012</year><volume>19</volume><fpage>793</fpage><lpage>797</lpage><pub-id pub-id-type="pmid">23289356</pub-id>
</element-citation></ref><ref id="B42-pharmaceutics-17-00212"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iliev</surname><given-names>Y.T.</given-names></name>
<name><surname>Tufkova</surname><given-names>S.G.</given-names></name>
<name><surname>Zagorov</surname><given-names>M.Y.</given-names></name>
<name><surname>Nikolova</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Snake Venom Poisoning in the Plovdiv Region from 2004 to 2012</article-title><source>Folia Med.</source><year>2014</year><volume>56</volume><fpage>32</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.2478/folmed-2014-0005</pub-id><pub-id pub-id-type="pmid">24812920</pub-id>
</element-citation></ref><ref id="B43-pharmaceutics-17-00212"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Espino-Solis</surname><given-names>G.P.</given-names></name>
<name><surname>Ria&#x000f1;o-Umbarila</surname><given-names>L.</given-names></name>
<name><surname>Becerril</surname><given-names>B.</given-names></name>
<name><surname>Possani</surname><given-names>L.D.</given-names></name>
</person-group><article-title>Antidotes against Venomous Animals: State of the Art and Prospectives</article-title><source>J. Proteomics</source><year>2009</year><volume>72</volume><fpage>183</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/j.jprot.2009.01.020</pub-id><pub-id pub-id-type="pmid">19457345</pub-id>
</element-citation></ref><ref id="B44-pharmaceutics-17-00212"><label>44.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Paniagua</surname><given-names>D.</given-names></name>
<name><surname>Vergara</surname><given-names>I.</given-names></name>
<name><surname>Boyer</surname><given-names>L.</given-names></name>
<name><surname>Alag&#x000f3;n</surname><given-names>A.</given-names></name>
</person-group><article-title>Role of Lymphatic System on Snake Venom Absorption</article-title><source>Snake Venoms</source><person-group person-group-type="editor">
<name><surname>Gopalakrishnakone</surname><given-names>P.</given-names></name>
<name><surname>Inagaki</surname><given-names>H.</given-names></name>
<name><surname>Mukherjee</surname><given-names>A.K.</given-names></name>
<name><surname>Rahmy</surname><given-names>T.R.</given-names></name>
<name><surname>Vogel</surname><given-names>C.-W.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>Dordrecht, The Netherlands</publisher-loc><year>2015</year><fpage>1</fpage><lpage>19</lpage><isbn>978-94-007-6648-8</isbn></element-citation></ref><ref id="B45-pharmaceutics-17-00212"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paniagua</surname><given-names>D.</given-names></name>
<name><surname>Jim&#x000e9;nez</surname><given-names>L.</given-names></name>
<name><surname>Romero</surname><given-names>C.</given-names></name>
<name><surname>Vergara</surname><given-names>I.</given-names></name>
<name><surname>Calder&#x000f3;n</surname><given-names>A.</given-names></name>
<name><surname>Benard</surname><given-names>M.</given-names></name>
<name><surname>Bernas</surname><given-names>M.J.</given-names></name>
<name><surname>Rilo</surname><given-names>H.</given-names></name>
<name><surname>De Roodt</surname><given-names>A.</given-names></name>
<name><surname>D&#x02019;Suze</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Lymphatic Route of Transport and Pharmacokinetics of <italic toggle="yes">Micrurus Fulvius</italic> (Coral Snake) Venom in Sheep</article-title><source>Lymphology</source><year>2012</year><volume>45</volume><fpage>144</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">23700761</pub-id>
</element-citation></ref><ref id="B46-pharmaceutics-17-00212"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Porter</surname><given-names>C.J.H.</given-names></name>
<name><surname>Edwards</surname><given-names>G.A.</given-names></name>
<name><surname>Charman</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Lymphatic Transport of Proteins after s.c. Injection: Implications of Animal Model Selection</article-title><source>Adv. Drug Deliv. Rev.</source><year>2001</year><volume>50</volume><fpage>157</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(01)00153-3</pub-id><pub-id pub-id-type="pmid">11489338</pub-id>
</element-citation></ref><ref id="B47-pharmaceutics-17-00212"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ismail</surname><given-names>M.</given-names></name>
<name><surname>Abd-Elsalam</surname><given-names>M.A.</given-names></name>
<name><surname>Al-Ahaidib</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Pharmacokinetics of 125I-Labelled <italic toggle="yes">Walterinnesia Aegyptia</italic> Venom and Its Specific Antivenins: Flash Absorption and Distribution of the Venom and Its Toxin versus Slow Absorption and Distribution of IgG, F(Ab&#x02019;)2 and F(Ab) of the Antivenin</article-title><source>Toxicon</source><year>1998</year><volume>36</volume><fpage>93</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/S0041-0101(97)00062-7</pub-id><pub-id pub-id-type="pmid">9604285</pub-id>
</element-citation></ref><ref id="B48-pharmaceutics-17-00212"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paniagua</surname><given-names>D.</given-names></name>
<name><surname>Vergara</surname><given-names>I.</given-names></name>
<name><surname>Rom&#x000e1;n</surname><given-names>R.</given-names></name>
<name><surname>Romero</surname><given-names>C.</given-names></name>
<name><surname>Benard-Valle</surname><given-names>M.</given-names></name>
<name><surname>Calder&#x000f3;n</surname><given-names>A.</given-names></name>
<name><surname>Jim&#x000e9;nez</surname><given-names>L.</given-names></name>
<name><surname>Bernas</surname><given-names>M.J.</given-names></name>
<name><surname>Witte</surname><given-names>M.H.</given-names></name>
<name><surname>Boyer</surname><given-names>L.V.</given-names></name>
<etal/>
</person-group><article-title>Antivenom Effect on Lymphatic Absorption and Pharmacokinetics of Coral Snake Venom Using a Large Animal Model</article-title><source>Clin. Toxicol.</source><year>2019</year><volume>57</volume><fpage>727</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1080/15563650.2018.1550199</pub-id><pub-id pub-id-type="pmid">30773936</pub-id>
</element-citation></ref><ref id="B49-pharmaceutics-17-00212"><label>49.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Guidelines for the Production, Control and Regulation of Snake Antivenom Immunoglobulins</article-title><source>WHO Expert Committee on Biological Standardization: Sixty-Seventh Report</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2017</year><fpage>197</fpage><lpage>388</lpage><isbn>978-92-4-121013-3</isbn></element-citation></ref><ref id="B50-pharmaceutics-17-00212"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Woo</surname><given-names>S.</given-names></name>
<name><surname>Jusko</surname><given-names>W.J.</given-names></name>
</person-group><article-title>Interspecies Comparisons of Pharmacokinetics and Pharmacodynamics of Recombinant Human Erythropoietin</article-title><source>Drug Metab. Dispos.</source><year>2007</year><volume>35</volume><fpage>1672</fpage><lpage>1678</lpage><pub-id pub-id-type="doi">10.1124/dmd.107.015248</pub-id><pub-id pub-id-type="pmid">17576810</pub-id>
</element-citation></ref><ref id="B51-pharmaceutics-17-00212"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scheerlinck</surname><given-names>J.P.Y.</given-names></name>
<name><surname>Snibson</surname><given-names>K.J.</given-names></name>
<name><surname>Bowles</surname><given-names>V.M.</given-names></name>
<name><surname>Sutton</surname><given-names>P.</given-names></name>
</person-group><article-title>Biomedical Applications of Sheep Models: From Asthma to Vaccines</article-title><source>Trends Biotechnol.</source><year>2008</year><volume>26</volume><fpage>259</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2008.02.002</pub-id><pub-id pub-id-type="pmid">18353472</pub-id>
</element-citation></ref><ref id="B52-pharmaceutics-17-00212"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ducrot</surname><given-names>C.</given-names></name>
<name><surname>Hom</surname><given-names>B.B.</given-names></name>
<name><surname>B&#x000e9;ringue</surname><given-names>V.</given-names></name>
<name><surname>Coulon</surname><given-names>J.</given-names></name>
<name><surname>Fourichon</surname><given-names>C.</given-names></name>
<name><surname>Gu&#x000e9;rin</surname><given-names>J.</given-names></name>
<name><surname>Krebs</surname><given-names>S.</given-names></name>
<name><surname>Rainard</surname><given-names>P.</given-names></name>
<name><surname>Schwartz-cornil</surname><given-names>I.</given-names></name>
<name><surname>Torny</surname><given-names>D.</given-names></name>
</person-group><article-title>Issues and Special Features of Animal Health Research</article-title><source>Veaterinary Res.</source><year>2011</year><volume>42</volume><fpage>96</fpage><pub-id pub-id-type="doi">10.1186/1297-9716-42-96</pub-id><pub-id pub-id-type="pmid">21864344</pub-id>
</element-citation></ref><ref id="B53-pharmaceutics-17-00212"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Percie Du Sert</surname><given-names>N.</given-names></name>
<name><surname>Hurst</surname><given-names>V.</given-names></name>
<name><surname>Ahluwalia</surname><given-names>A.</given-names></name>
<name><surname>Alam</surname><given-names>S.</given-names></name>
<name><surname>Avey</surname><given-names>M.T.</given-names></name>
<name><surname>Baker</surname><given-names>M.</given-names></name>
<name><surname>Browne</surname><given-names>W.J.</given-names></name>
<name><surname>Clark</surname><given-names>A.</given-names></name>
<name><surname>Cuthill</surname><given-names>I.C.</given-names></name>
<name><surname>Dirnagl</surname><given-names>U.</given-names></name>
<etal/>
</person-group><article-title>The ARRIVE Guidelines 2.0: Updated Guidelines for Reporting Animal Research</article-title><source>BMC Vet. Res.</source><year>2020</year><volume>4</volume><elocation-id>242</elocation-id><pub-id pub-id-type="doi">10.1136/bmjos-2020-100115</pub-id></element-citation></ref><ref id="B54-pharmaceutics-17-00212"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Halassy</surname><given-names>B.</given-names></name>
<name><surname>Habjanec</surname><given-names>L.</given-names></name>
<name><surname>Balija</surname><given-names>M.L.</given-names></name>
<name><surname>Kurtovi&#x00107;</surname><given-names>T.</given-names></name>
<name><surname>Brgles</surname><given-names>M.</given-names></name>
<name><surname>Kri&#x0017e;aj</surname><given-names>I.</given-names></name>
</person-group><article-title>Ammodytoxin Content of <italic toggle="yes">Vipera Ammodytes Ammodytes</italic> Venom as a Prognostic Factor for Venom Immunogenicity</article-title><source>Comp. Biochem. Physiol.-C Toxicol. Pharmacol.</source><year>2010</year><volume>151</volume><fpage>455</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/j.cbpc.2010.02.001</pub-id><pub-id pub-id-type="pmid">20139032</pub-id>
</element-citation></ref><ref id="B55-pharmaceutics-17-00212"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Huo</surname><given-names>M.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Xie</surname><given-names>S.</given-names></name>
</person-group><article-title>PKSolver: An Add-in Program for Pharmacokinetic and Pharmacodynamic Data Analysis in Microsoft Excel</article-title><source>Comput. Methods Programs Biomed.</source><year>2010</year><volume>99</volume><fpage>306</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/j.cmpb.2010.01.007</pub-id><pub-id pub-id-type="pmid">20176408</pub-id>
</element-citation></ref><ref id="B56-pharmaceutics-17-00212"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mora</surname><given-names>J.</given-names></name>
<name><surname>Mora</surname><given-names>R.</given-names></name>
<name><surname>Lomonte</surname><given-names>B.</given-names></name>
<name><surname>Guti&#x000e9;rrez</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Effects of <italic toggle="yes">Bothrops Asper</italic> Snake Venom on Lymphatic Vessels: Insights into a Hidden Aspect of Envenomation</article-title><source>PLoS Negl. Trop. Dis.</source><year>2008</year><volume>2</volume><elocation-id>e318</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0000318</pub-id><pub-id pub-id-type="pmid">18923712</pub-id>
</element-citation></ref><ref id="B57-pharmaceutics-17-00212"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maduwage</surname><given-names>K.P.</given-names></name>
<name><surname>Scorgie</surname><given-names>F.E.</given-names></name>
<name><surname>Lincz</surname><given-names>L.F.</given-names></name>
<name><surname>O&#x02019;Leary</surname><given-names>M.A.</given-names></name>
<name><surname>Isbister</surname><given-names>G.K.</given-names></name>
</person-group><article-title>Procoagulant Snake Venoms Have Differential Effects in Animal Plasmas: Implications for Antivenom Testing in Animal Models</article-title><source>Thromb. Res.</source><year>2016</year><volume>137</volume><fpage>174</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2015.12.002</pub-id><pub-id pub-id-type="pmid">26656242</pub-id>
</element-citation></ref><ref id="B58-pharmaceutics-17-00212"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rojas</surname><given-names>A.</given-names></name>
<name><surname>Vargas</surname><given-names>M.</given-names></name>
<name><surname>Ram&#x000ed;rez</surname><given-names>N.</given-names></name>
<name><surname>Estrada</surname><given-names>R.</given-names></name>
<name><surname>Segura</surname><given-names>&#x000c1;.</given-names></name>
<name><surname>Herrera</surname><given-names>M.</given-names></name>
<name><surname>Villalta</surname><given-names>M.</given-names></name>
<name><surname>G&#x000f3;mez</surname><given-names>A.</given-names></name>
<name><surname>Guti&#x000e9;rrez</surname><given-names>J.M.</given-names></name>
<name><surname>Le&#x000f3;n</surname><given-names>G.</given-names></name>
</person-group><article-title>Role of the Animal Model on the Pharmacokinetics of Equine-Derived Antivenoms</article-title><source>Toxicon</source><year>2013</year><volume>70</volume><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2013.03.013</pub-id><pub-id pub-id-type="pmid">23557996</pub-id>
</element-citation></ref><ref id="B59-pharmaceutics-17-00212"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sanhajariya</surname><given-names>S.</given-names></name>
<name><surname>Duffull</surname><given-names>S.B.</given-names></name>
<name><surname>Isbister</surname><given-names>G.K.</given-names></name>
</person-group><article-title>Pharmacokinetics of Snake Venom</article-title><source>Toxins</source><year>2018</year><volume>10</volume><elocation-id>73</elocation-id><pub-id pub-id-type="doi">10.3390/toxins10020073</pub-id><pub-id pub-id-type="pmid">29414889</pub-id>
</element-citation></ref><ref id="B60-pharmaceutics-17-00212"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krifi</surname><given-names>M.N.</given-names></name>
<name><surname>Savin</surname><given-names>S.</given-names></name>
<name><surname>Debray</surname><given-names>M.</given-names></name>
<name><surname>Bon</surname><given-names>C.</given-names></name>
<name><surname>El Ayeb</surname><given-names>M.</given-names></name>
<name><surname>Choumet</surname><given-names>V.</given-names></name>
</person-group><article-title>Pharmacokinetic Studies of Scorpion Venom before and after Antivenom Immunotherapy</article-title><source>Toxicon</source><year>2005</year><volume>45</volume><fpage>187</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2004.10.007</pub-id><pub-id pub-id-type="pmid">15626368</pub-id>
</element-citation></ref><ref id="B61-pharmaceutics-17-00212"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salmonson</surname><given-names>T.</given-names></name>
<name><surname>Danielson</surname><given-names>B.</given-names></name>
<name><surname>Wikstrom</surname><given-names>B.</given-names></name>
</person-group><article-title>The Pharmacokinetics of Recombinant Human Erythropoietin after Intravenous and Subcutaneous Administration to Healthy Subjects</article-title><source>Br. J. Clin. Pharmacol.</source><year>1990</year><volume>29</volume><fpage>709</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1990.tb03692.x</pub-id><pub-id pub-id-type="pmid">2378790</pub-id>
</element-citation></ref><ref id="B62-pharmaceutics-17-00212"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>V&#x000e1;zquez</surname><given-names>H.</given-names></name>
<name><surname>Ch&#x000e1;vez-Haro</surname><given-names>A.</given-names></name>
<name><surname>Garc&#x000ed;a-Ubbelohde</surname><given-names>W.</given-names></name>
<name><surname>Paniagua-Sol&#x000ed;s</surname><given-names>J.</given-names></name>
<name><surname>Alag&#x000f3;n</surname><given-names>A.</given-names></name>
<name><surname>Sevcik</surname><given-names>C.</given-names></name>
</person-group><article-title>Pharmacokinetics of a F(Ab&#x02032;)2 Scorpion Antivenom Administered Intramuscularly in Healthy Human Volunteers</article-title><source>Int. Immunopharmacol.</source><year>2010</year><volume>10</volume><fpage>1318</fpage><lpage>1324</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2010.08.018</pub-id><pub-id pub-id-type="pmid">20849955</pub-id>
</element-citation></ref><ref id="B63-pharmaceutics-17-00212"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boyer</surname><given-names>L.V.</given-names></name>
<name><surname>Seifert</surname><given-names>S.A.</given-names></name>
<name><surname>Clark</surname><given-names>R.F.</given-names></name>
<name><surname>McNally</surname><given-names>J.T.</given-names></name>
<name><surname>Williams</surname><given-names>S.R.</given-names></name>
<name><surname>Nordt</surname><given-names>S.P.</given-names></name>
<name><surname>Walter</surname><given-names>F.G.</given-names></name>
<name><surname>Dart</surname><given-names>R.C.</given-names></name>
</person-group><article-title>Recurrent and Persistent Coagulopathy Following Pit Viper Envenomation</article-title><source>Arch. Intern. Med.</source><year>1999</year><volume>159</volume><fpage>706</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1001/archinte.159.7.706</pub-id><pub-id pub-id-type="pmid">10218750</pub-id>
</element-citation></ref><ref id="B64-pharmaceutics-17-00212"><label>64.</label><element-citation publication-type="confproc"><person-group person-group-type="author">
<name><surname>Hla</surname><given-names>P.</given-names></name>
<name><surname>Thein</surname><given-names>T.</given-names></name>
<name><surname>Maung</surname><given-names>M.T.</given-names></name>
<name><surname>Myint</surname><given-names>L.</given-names></name>
<name><surname>Tin</surname><given-names>N.S.</given-names></name>
</person-group><article-title>Circulating Antivenom Levels in Human Subjects Following Intramuscular Administration of Russell&#x02019;s Viper Antivenom</article-title><source>Proceedings of the Medical Research Congress</source><conf-loc>Yangon, Myanmar</conf-loc><conf-date>19&#x02013;22 December 1989</conf-date><volume>Volume 116</volume></element-citation></ref><ref id="B65-pharmaceutics-17-00212"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seifert</surname><given-names>S.A.</given-names></name>
<name><surname>Boyer</surname><given-names>L.V.</given-names></name>
</person-group><article-title>Recurrence Phenomena after Immunoglobulin Therapy for Snake Envenomations: Part 1. Pharmacokinetics and Pharmacodynamics of Immunoglobulin Antivenoms and Related Antibodies</article-title><source>Ann. Emerg. Med.</source><year>2001</year><volume>37</volume><fpage>189</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1067/mem.2001.113135</pub-id><pub-id pub-id-type="pmid">11174238</pub-id>
</element-citation></ref><ref id="B66-pharmaceutics-17-00212"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>V&#x000e1;zquez</surname><given-names>H.</given-names></name>
<name><surname>Ch&#x000e1;vez-Haro</surname><given-names>A.</given-names></name>
<name><surname>Garc&#x000ed;a-Ubbelohde</surname><given-names>W.</given-names></name>
<name><surname>Mancilla-Nava</surname><given-names>R.</given-names></name>
<name><surname>Paniagua-Sol&#x000ed;s</surname><given-names>J.</given-names></name>
<name><surname>Alag&#x000f3;n</surname><given-names>A.</given-names></name>
<name><surname>Sevcik</surname><given-names>C.</given-names></name>
</person-group><article-title>Pharmacokinetics of a F(Ab&#x02032;)2 Scorpion Antivenom in Healthy Human Volunteers</article-title><source>Toxicon</source><year>2005</year><volume>46</volume><fpage>797</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2005.08.010</pub-id><pub-id pub-id-type="pmid">16197974</pub-id>
</element-citation></ref><ref id="B67-pharmaceutics-17-00212"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Le&#x000f3;n</surname><given-names>G.</given-names></name>
<name><surname>Herrera</surname><given-names>M.</given-names></name>
<name><surname>Segura</surname><given-names>&#x000c1;.</given-names></name>
<name><surname>Villalta</surname><given-names>M.</given-names></name>
<name><surname>Vargas</surname><given-names>M.</given-names></name>
<name><surname>Guti&#x000e9;rrez</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Pathogenic Mechanisms Underlying Adverse Reactions Induced by Intravenous Administration of Snake Antivenoms</article-title><source>Toxicon</source><year>2013</year><volume>76</volume><fpage>63</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2013.09.010</pub-id><pub-id pub-id-type="pmid">24055551</pub-id>
</element-citation></ref><ref id="B68-pharmaceutics-17-00212"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dart</surname><given-names>R.C.</given-names></name>
<name><surname>McNally</surname><given-names>J.</given-names></name>
</person-group><article-title>Efficacy, Safety, and Use of Snake Antivenoms in the United States</article-title><source>Ann. Emerg. Med.</source><year>2001</year><volume>37</volume><fpage>181</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1067/mem.2001.113372</pub-id><pub-id pub-id-type="pmid">11174237</pub-id>
</element-citation></ref><ref id="B69-pharmaceutics-17-00212"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morais</surname><given-names>V.</given-names></name>
<name><surname>Berasain</surname><given-names>P.</given-names></name>
<name><surname>Ifr&#x000e1;n</surname><given-names>S.</given-names></name>
<name><surname>Carreira</surname><given-names>S.</given-names></name>
<name><surname>Tortorella</surname><given-names>M.N.</given-names></name>
<name><surname>Negr&#x000ed;n</surname><given-names>A.</given-names></name>
<name><surname>Massaldi</surname><given-names>H.</given-names></name>
</person-group><article-title>Humoral Immune Responses to Venom and Antivenom of Patients Bitten by Bothrops Snakes</article-title><source>Toxicon</source><year>2012</year><volume>59</volume><fpage>315</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2011.12.006</pub-id><pub-id pub-id-type="pmid">22206812</pub-id>
</element-citation></ref><ref id="B70-pharmaceutics-17-00212"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laustsen</surname><given-names>A.H.</given-names></name>
<name><surname>Mar&#x000ed;a Guti&#x000e9;rrez</surname><given-names>J.</given-names></name>
<name><surname>Knudsen</surname><given-names>C.</given-names></name>
<name><surname>Johansen</surname><given-names>K.H.</given-names></name>
<name><surname>Berm&#x000fa;dez-M&#x000e9;ndez</surname><given-names>E.</given-names></name>
<name><surname>Cerni</surname><given-names>F.A.</given-names></name>
<name><surname>J&#x000fc;rgensen</surname><given-names>J.A.</given-names></name>
<name><surname>Ledsgaard</surname><given-names>L.</given-names></name>
<name><surname>Martos-Esteban</surname><given-names>A.</given-names></name>
<name><surname>&#x000d8;hlenschl&#x000e6;ger</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Pros and Cons of Different Therapeutic Antibody Formats for Recombinant Antivenom Development</article-title><source>Toxicon</source><year>2018</year><volume>146</volume><fpage>151</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2018.03.004</pub-id><pub-id pub-id-type="pmid">29534892</pub-id>
</element-citation></ref><ref id="B71-pharmaceutics-17-00212"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mayers</surname><given-names>C.N.</given-names></name>
<name><surname>Veall</surname><given-names>S.</given-names></name>
<name><surname>Bedford</surname><given-names>R.J.</given-names></name>
<name><surname>Holley</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Anti-Immunoglobulin Responses to IgG, F(Ab&#x02032;)2, and Fab Botulinum Antitoxins in Mice</article-title><source>Immunopharmacol. Immunotoxicol.</source><year>2003</year><volume>25</volume><fpage>397</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1081/IPH-120024507</pub-id><pub-id pub-id-type="pmid">19180802</pub-id>
</element-citation></ref><ref id="B72-pharmaceutics-17-00212"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luk&#x00161;i&#x00107;</surname><given-names>B.</given-names></name>
<name><surname>&#x0010c;uli&#x00107;</surname><given-names>V.</given-names></name>
<name><surname>Stri&#x0010d;evi&#x00107;</surname><given-names>L.</given-names></name>
<name><surname>Brizi&#x00107;</surname><given-names>I.</given-names></name>
<name><surname>Poljak</surname><given-names>N.K.</given-names></name>
<name><surname>Tadi&#x00107;</surname><given-names>Z.</given-names></name>
</person-group><article-title>Infant Death after Nose-Horned Viper (<italic toggle="yes">Vipera Ammodytes Ammodytes</italic>) Bite in Croatia: A Case Report</article-title><source>Toxicon</source><year>2010</year><volume>56</volume><fpage>1506</fpage><lpage>1509</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2010.08.009</pub-id><pub-id pub-id-type="pmid">20813122</pub-id>
</element-citation></ref><ref id="B73-pharmaceutics-17-00212"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frangides</surname><given-names>C.Y.</given-names></name>
<name><surname>Koulouras</surname><given-names>V.</given-names></name>
<name><surname>Kouni</surname><given-names>S.N.</given-names></name>
<name><surname>Tzortzatos</surname><given-names>G.V.</given-names></name>
<name><surname>Nikolaou</surname><given-names>A.</given-names></name>
<name><surname>Pneumaticos</surname><given-names>J.</given-names></name>
<name><surname>Pierrakeas</surname><given-names>C.</given-names></name>
<name><surname>Niarchos</surname><given-names>C.</given-names></name>
<name><surname>Kounis</surname><given-names>N.G.</given-names></name>
<name><surname>Koutsojannis</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Snake Venom Poisoning in Greece. Experiences with 147 Cases</article-title><source>Eur. J. Intern. Med.</source><year>2006</year><volume>17</volume><fpage>14</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.ejim.2005.10.001</pub-id></element-citation></ref><ref id="B74-pharmaceutics-17-00212"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dobaja Borak</surname><given-names>M.</given-names></name>
<name><surname>Grenc</surname><given-names>D.</given-names></name>
<name><surname>Reber&#x00161;ek</surname><given-names>K.</given-names></name>
<name><surname>Podgornik</surname><given-names>H.</given-names></name>
<name><surname>Leonardi</surname><given-names>A.</given-names></name>
<name><surname>Kurtovi&#x00107;</surname><given-names>T.</given-names></name>
<name><surname>Halassy</surname><given-names>B.</given-names></name>
<name><surname>Kri&#x0017e;aj</surname><given-names>I.</given-names></name>
<name><surname>Brvar</surname><given-names>M.</given-names></name>
</person-group><article-title>Reversible and Transient Thrombocytopenia of Functional Platelets Induced by Nose-Horned Viper Venom</article-title><source>Thromb. Res.</source><year>2023</year><volume>229</volume><fpage>152</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2023.07.005</pub-id><pub-id pub-id-type="pmid">37454466</pub-id>
</element-citation></ref><ref id="B75-pharmaceutics-17-00212"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dobaja Borak</surname><given-names>M.</given-names></name>
<name><surname>Babi&#x00107;</surname><given-names>&#x0017d;.</given-names></name>
<name><surname>Caganova</surname><given-names>B.</given-names></name>
<name><surname>Grenc</surname><given-names>D.</given-names></name>
<name><surname>Karabuva</surname><given-names>S.</given-names></name>
<name><surname>Kolpach</surname><given-names>Z.</given-names></name>
<name><surname>Krakowiak</surname><given-names>A.</given-names></name>
<name><surname>Kolesnikova</surname><given-names>V.</given-names></name>
<name><surname>Luk&#x00161;i&#x00107;</surname><given-names>B.</given-names></name>
<name><surname>Pap</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Viper Envenomation in Central and Southeastern Europe: A Multicentre Study</article-title><source>Clin. Toxicol.</source><year>2023</year><volume>61</volume><fpage>656</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1080/15563650.2023.2273761</pub-id><pub-id pub-id-type="pmid">37988116</pub-id>
</element-citation></ref><ref id="B76-pharmaceutics-17-00212"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marinov</surname><given-names>I.</given-names></name>
<name><surname>Atanasov</surname><given-names>V.N.</given-names></name>
<name><surname>Stankova</surname><given-names>E.</given-names></name>
<name><surname>Duhalov</surname><given-names>D.</given-names></name>
<name><surname>Petrova</surname><given-names>S.</given-names></name>
<name><surname>Hubenova</surname><given-names>A.</given-names></name>
</person-group><article-title>Severe Coagulopathy after <italic toggle="yes">Vipera Ammodytes Ammodytes</italic> Snakebite in Bulgaria: A Case Report</article-title><source>Toxicon</source><year>2010</year><volume>56</volume><fpage>1066</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2010.06.010</pub-id><pub-id pub-id-type="pmid">20600226</pub-id>
</element-citation></ref><ref id="B77-pharmaceutics-17-00212"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luk&#x00161;i&#x00107;</surname><given-names>B.</given-names></name>
<name><surname>Karabuva</surname><given-names>S.</given-names></name>
<name><surname>Marki&#x00107;</surname><given-names>J.</given-names></name>
<name><surname>Poli&#x00107;</surname><given-names>B.</given-names></name>
<name><surname>Kova&#x0010d;evi&#x00107;</surname><given-names>T.</given-names></name>
<name><surname>M&#x0011b;strovi&#x00107;</surname><given-names>J.</given-names></name>
<name><surname>Kri&#x0017e;aj</surname><given-names>I.</given-names></name>
</person-group><article-title>Thrombocytopenic Purpura Following Envenomation by the Nose-Horned Viper (<italic toggle="yes">Vipera Ammodytes Ammodytes</italic>): Two Case Reports</article-title><source>Medicine</source><year>2018</year><volume>97</volume><fpage>e13737</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000013737</pub-id><pub-id pub-id-type="pmid">30593149</pub-id>
</element-citation></ref><ref id="B78-pharmaceutics-17-00212"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Petricevich</surname><given-names>V.L.</given-names></name>
</person-group><article-title>Cytokine and Nitric Oxide Production Following Severe Envenomation</article-title><source>Curr. Drug Targets Inflamm. Allergy</source><year>2004</year><volume>3</volume><fpage>325</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.2174/1568010043343642</pub-id><pub-id pub-id-type="pmid">15379602</pub-id>
</element-citation></ref><ref id="B79-pharmaceutics-17-00212"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hsu</surname><given-names>C.P.</given-names></name>
<name><surname>Chuang</surname><given-names>J.F.</given-names></name>
<name><surname>Hsu</surname><given-names>Y.P.</given-names></name>
<name><surname>Wang</surname><given-names>S.Y.</given-names></name>
<name><surname>Fu</surname><given-names>C.Y.</given-names></name>
<name><surname>Yuan</surname><given-names>K.C.</given-names></name>
<name><surname>Chen</surname><given-names>C.H.</given-names></name>
<name><surname>Kang</surname><given-names>S.C.</given-names></name>
<name><surname>Liao</surname><given-names>C.H.</given-names></name>
</person-group><article-title>Predictors of the Development of Post-Snakebite Compartment Syndrome</article-title><source>Scand. J. Trauma. Resusc. Emerg. Med.</source><year>2015</year><volume>23</volume><fpage>97</fpage><pub-id pub-id-type="doi">10.1186/s13049-015-0179-y</pub-id><pub-id pub-id-type="pmid">26561300</pub-id>
</element-citation></ref><ref id="B80-pharmaceutics-17-00212"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morris</surname><given-names>N.M.</given-names></name>
<name><surname>Blee</surname><given-names>J.A.</given-names></name>
<name><surname>Hauert</surname><given-names>S.</given-names></name>
</person-group><article-title>Developing a Computational Pharmacokinetic Model of Systemic Snakebite Envenomation and Antivenom Treatment</article-title><source>Toxicon</source><year>2022</year><volume>215</volume><fpage>77</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2022.06.006</pub-id><pub-id pub-id-type="pmid">35716719</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-00212-f001"><label>Figure 1</label><caption><p>The venom-treated animals are divided into two groups, according to the route of antivenom administration. In one group (<italic toggle="yes">n</italic> = 8), antivenom is administered by <italic toggle="yes">i.m.</italic> bolus. In another group (<italic toggle="yes">n</italic> = 8), antivenom is administered by <italic toggle="yes">i.v.</italic> infusion over 30 min. In each group, half of the animals are used for lymph sampling (L<italic toggle="yes"><sub>i.m</sub>.</italic> and L<italic toggle="yes"><sub>i.v.</sub></italic> groups). The other half are used for blood sampling (S<italic toggle="yes"><sub>i.m.</sub></italic> and S<italic toggle="yes"><sub>i.v.</sub></italic> groups).</p></caption><graphic xlink:href="pharmaceutics-17-00212-g001" position="float"/></fig><fig position="float" id="pharmaceutics-17-00212-f002"><label>Figure 2</label><caption><p>Protocol for lymph (<bold>a</bold>) and blood sampling (<bold>b</bold>) in envenomed and antivenom-treated sheep.</p></caption><graphic xlink:href="pharmaceutics-17-00212-g002" position="float"/></fig><fig position="float" id="pharmaceutics-17-00212-f003"><label>Figure 3</label><caption><p>The lymphatic absorption in envenomed and antivenom-treated sheep. The rate of absorption and the total amount reaching the lymph during a sampling period (AUC<sub>0-<italic toggle="yes">t</italic></sub>) of <italic toggle="yes">i.m.</italic> and <italic toggle="yes">i.v.</italic> antivenoms (<bold>a</bold>), as well as of the venom (<bold>b</bold>) and ammodytoxins (Atxs), in relation to the route of antivenom administration (<bold>c</bold>). Comparisons between the L<italic toggle="yes"><sub>i.m.</sub></italic> group, treated with <italic toggle="yes">i.m.</italic> antivenom, and the L<italic toggle="yes"><sub>i.v.</sub></italic> group, treated with <italic toggle="yes">i.v.</italic> antivenom, are evaluated by U-test at a significance level of <italic toggle="yes">p</italic> &#x0003c; 0.05.</p></caption><graphic xlink:href="pharmaceutics-17-00212-g003" position="float"/></fig><fig position="float" id="pharmaceutics-17-00212-f004"><label>Figure 4</label><caption><p>Representative example of the cumulative increase in the venom, ammodytoxins (Atxs) and antivenom quantities absorbed into the lymphatic circulation after the <italic toggle="yes">s.c.</italic> injection of venom and <italic toggle="yes">i.m.</italic> (<bold>a</bold>) or <italic toggle="yes">i.v.</italic> injection of antivenom (<bold>b</bold>).</p></caption><graphic xlink:href="pharmaceutics-17-00212-g004" position="float"/></fig><fig position="float" id="pharmaceutics-17-00212-f005"><label>Figure 5</label><caption><p>Venom and antivenom pharmacokinetics in the systemic circulation. Representative pharmacokinetic profiles of venom, ammodytoxins (Atxs) and <italic toggle="yes">i.m.</italic> administered antivenom in the systemic circulation of a sheep from the S<italic toggle="yes"><sub>i.m.</sub></italic> group during the entire sampling period and during the first 24 h (excerpt) (<bold>a</bold>). Representative pharmacokinetic profiles of venom, Atxs and <italic toggle="yes">i.v.</italic> administered antivenom in the systemic circulation of a sheep from the S<italic toggle="yes"><sub>i.v.</sub></italic> group during the entires ampling period and during the first 24 h (excerpt) (<bold>b</bold>). Results are presented as the mean of three independent measurements &#x000b1; standard error.</p></caption><graphic xlink:href="pharmaceutics-17-00212-g005" position="float"/></fig><fig position="float" id="pharmaceutics-17-00212-f006"><label>Figure 6</label><caption><p>Pharmacokinetic parameters in the sera of envenomed and antivenom-treated sheep. The elimination half-life (<italic toggle="yes">t</italic><sub>1/2</sub>), time to reach maximum concentration (<italic toggle="yes">t</italic><sub>max</sub>) and maximum concentration (<italic toggle="yes">c</italic><sub>max</sub>), volume of distribution (<italic toggle="yes">V</italic><sub>z</sub>), mean residence time (MRT), total amount in the bloodstream over the duration of the measurement period (AUC<sub>0-<italic toggle="yes">t</italic></sub>) and clearance (CL) of antivenoms (<bold>a</bold>), as well as of the venom (<bold>b</bold>) and ammodytoxins (Atxs) (<bold>c</bold>), in relation to the route of antivenom administration, are presented. Comparisons between the S<italic toggle="yes"><sub>i.m.</sub></italic> group, treated with <italic toggle="yes">i.m.</italic> antivenom, and the S<italic toggle="yes"><sub>i.v.</sub></italic> group, treated with <italic toggle="yes">i.v.</italic> antivenom, are evaluated by U-test at a significance level of <italic toggle="yes">p</italic> &#x0003c; 0.05.</p></caption><graphic xlink:href="pharmaceutics-17-00212-g006" position="float"/></fig><fig position="float" id="pharmaceutics-17-00212-f007"><label>Figure 7</label><caption><p>Impact of <italic toggle="yes">i.m.</italic> and <italic toggle="yes">i.v.</italic> antivenoms on the venom-induced blood disorders. Fibrinogen concentration (<bold>a</bold>), degree of aggregation (<bold>b</bold>), platelet (<bold>c</bold>) and leukocyte count (<bold>d</bold>) are determined in blood samples taken before and after envenoming and during the post-treatment period. The results are given as the mean of the values obtained for each animal.</p></caption><graphic xlink:href="pharmaceutics-17-00212-g007" position="float"/></fig><fig position="float" id="pharmaceutics-17-00212-f008"><label>Figure 8</label><caption><p>Humoral response to <italic toggle="yes">i.m.</italic> and <italic toggle="yes">i.v.</italic> antivenoms. Concentrations of anti-antivenom IgGs in serum samples taken 2 weeks after antivenom administration are determined by ELISA and expressed in arbitrary units (AUs) per mL. The comparison between the S<italic toggle="yes"><sub>i.m.</sub></italic> group, treated with <italic toggle="yes">i.m.</italic> antivenom, and the S<italic toggle="yes"><sub>i.v.</sub></italic> group, treated with <italic toggle="yes">i.v.</italic> antivenom, is evaluated by U-test at a significance level of <italic toggle="yes">p</italic> &#x0003c; 0.05.</p></caption><graphic xlink:href="pharmaceutics-17-00212-g008" position="float"/></fig></floats-group></article>